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Myeloid cells in the CNS counteract neuroinflammation via cellular responses to T 
cell infiltration 
Beatrice Waßer, Dipl. Chem 
Thesis advisors: xxx and xxx. 
ABSTRACT 
Multiple Sclerosis (MS) is an inflammatory disabling disease of the central nervous system 
(CNS) and is one of the most frequent causes of irreversible disability in young people. Both 
adaptive and innate immune cells infiltrate the CNS during MS and in its animal model 
experimental autoimmune encephalomyelitis (EAE). This thesis focuses on the impact of 
CNS-infiltrating and CNS-resident myeloid cells during neuroinflammation. Using deep mRNA 
sequencing (RNA-Seq), three distinct markers of alternatively activated myeloid cells (aaMC), 
namely Ms4a8a, Ym1 and Arginase1, were here identified to be more highly expressed in the 
CNS during exacerbation of the disease compared to all other considered time points of 
disease development. This upregulation was detected in two different mouse strains despite 
strong genetic differences. aaMC exhibit beneficial properties during the disease and the 
upregulation of aaMC markers during the active state of the disease suggests the attempt of 
myeloid cells in the CNS to counteract disease progression. Among myeloid cells, microglia 
are CNS-resident and therefore particularly relevant regarding CNS inflammation. In the here 
presented work it was shown that microglia attempt to remove invading pathogenic T cells 
from the CNS tissue during the disease. Intravital two-photon imaging revealed that 
microglia intensely contacted pathogenic Th17 cells in inflammatory lesions. Strikingly, 
microglia were able to respond to CNS inflammation by engulfing invading T cells. This as of 
yet undefined engulfment process targeted fully viable T cells and was dependent on the 
strength of both T cell and microglial activation. While microglial activation significantly 
increased engulfment processes, inhibition of T cell activity decreased the engulfment of T 
cells, altogether clearly emphasizing the importance of engulfment processes in 
inflammation. The engulfment of living T cells in the CNS may therefore reflect a general 
defense mechanism of the CNS towards invading activated cells. In sum, both the 
upregulation of aaMC markers during the exacerbation of the disease as well as the 
engulfment of CNS-invading Th17 cells could serve as myeloid cell-mediated mechanisms to 
counteract neuroinflammation. 
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Myeloide Zellen im ZNS wirken einer Neuroinflammation durch zelluläre 
Reaktionen auf die T-Zell-Infiltration entgegen 
Beatrice Waßer, Dipl. Chem 
Betreuer: xxx und xxx. 
ZUSAMMENFASSUNG 
Multiple Sklerose (MS) ist eine inflammatorische Erkrankung des zentralen Nervensystems 
(ZNS) und gehört zu den häufigsten Ursachen irreversibler Behinderungen im jungen 
Erwachsenenalter. Sowohl Immunzellen der angeborenen als auch Immunzellen der 
adaptiven Immunantwort infiltrieren das ZNS während der MS und ebenso in deren 
Tiermodell, der experimentellen autoimmunen Enzephallomyelitis (EAE). In dieser Arbeit 
steht die Bedeutung von ZNS-infiltrierenden und ZNS-residenten myeloiden Zellen während 
der Neuro-Inflammation im Fokus. Mittels RNA-Sequenzierung wurden dabei drei Gene 
identifiziert, die während eines verschärften Symptom-Auftretens höher exprimiert waren, 
als zu allen anderen betrachteten Zeitpunkten der Erkrankung. Die Expression dieser drei 
Gene, namentlich Ms4a8a, YM1 und Arginase1, sind kennzeichnend für sogenannte 
alternativ-aktivierte myleoide Zellen, welche den Krankheitsverlauf begünstigen können. Die 
erhöhte Expression dieser drei Gene während der aktiven Phase der Erkrankung 
verdeutlichte die Intention myeloider Zellen des ZNS, dem Fortschreiten der Erkrankung 
entgegenzuwirken. Mikroglia sind die ZNS-residenten myeloiden Zellen und sind daher von 
besonderer Bedeutung während der ZNS-Inflammation. In dieser Arbeit konnte gezeigt 
werden, dass Mikroglia während der EAE versuchten, pathogene, infiltrierende T-Zellen aus 
dem ZNS-Gewebe zu entfernen. Intravitale zwei-Photonen-Mikroskopie zeigte, dass 
Mikroglia in inflammatorischen Läsionen intensive Kontakte mit Th17-Zellen eingingen. 
Mikroglia zeigten dabei die bemerkenswerte Fähigkeit auf die Inflammation zu reagieren, 
indem sie sich einwandernde T-Zellen einverleibten. Dieser bisher unbekannte Prozess des 
Einverleibens zielte auch auf vitale T-Zellen ab und war dabei sowohl abhängig von der T-
Zell-Aktivität, als auch von der Mikroglia-Aktivität. Während die Aktivierung der Mikroglia-
Zellen zu einem signifikanten Anstieg des Einverleibungs-Prozesses führte, erniedrigte eine 
Inhibierung der T-Zell-Aktivität selbigen Prozess. Das Einverleiben von T-Zellen spiegelt daher 
einen möglicherweise generellen Abwehr-Mechanismus des ZNS gegenüber aktivierten, 
einwandernden Zellen wider. 
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10 
 
1)  Introduction 
1.1) Multiple Sclerosis and Experimental autoimmune Encephalomyelitis 
Multiple Sclerosis (MS) is an inflammatory disabling disease of the central nervous system 
(CNS), mainly manifesting in young adults and thereby one of the most frequent causes of 
irreversible disability in young people (Compston and Coles, 2008; Larochelle et al., 2016). 
Characteristic symptoms of MS include, but are not restricted to, loss of vision, motor 
impairments, pain, cognitive deficits and fatigue (Compston and Coles, 2008). Although the 
disease progression in individual patients is highly variable, the disease starts most 
commonly in a relapsing-remitting manner (relapsing-remitting MS, RRMS), in which acute 
exacerbations alternate with time periods with no or only marginal clinical symptoms 
(Compston and Coles, 2008; Lublin and Reingold, 1996; Siffrin et al., 2010b). 65 % of MS 
patients subsequently develop secondary progressive MS (SPMS), characterized by the 
continuous increase of disease severity leading to chronic disease activity. Only low 
 
Figure 1: Schematic disease progression in MS and EAE. The time-dependent progression of clinical MS-
symptoms (disability) is shown during relapsing-remitting MS, secondary progressive MS and primary 
progressive MS in human (left). Similarly, the time-dependent progression of EAE symptoms (score) is 
shown during relapsing remitting EAE in SJL/J mice (right, upper part) and during chronic progressive EAE in 
C57BL/6 mice (right, lower part). 
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percentages of patients (≈20 %) suffer from primary progressive MS (PPMS), in which the 
illness is progressive from the onset of the disease (Compston and Coles, 2008; Larochelle et 
al., 2016) (Figure 1). 
To investigate the pathophysiological mechanisms during the disease, the animal model of 
MS, experimental autoimmune encephalomyelitis (EAE) is widely used (Croxford et al., 
2011). Active EAE is induced in mice by the subcutaneous (s.c.) injection of a CNS resident 
peptide (e.g., myelin oligodendrocyte glycoprotein (MOG) or myelin proteolipid protein 
(PLP)), which stimulates the active generation of endogenous autoreactive immune cells (’t 
Hart et al., 2011). Analogous to MS patients, EAE-diseased mice exhibit different disease 
courses. Notably, the s.c. injection of PLP139-151 usually induces a relapsing-remitting EAE in 
SJL/J mice (McRae et al., 1992), while the s.c. injection of MOG35-55 usually induces a chronic 
progressive disease in C57BL/6 mice (Mendel et al., 1995; Thakker et al., 2007) (Figure 1). 
The adoptive transfer of pathogenic T helper (Th)17 cells into SJL/J or C57BL/6 recipient mice 
similarly causes a chronic progressive disease course (Aktas et al., 2005; Flügel et al., 2001; 
Siffrin et al., 2010a). 
Disease pathology and the mechanisms responsible for the different disease courses are still 
poorly understood in humans and in mice. However, it is well known that immune cells 
infiltrate the CNS both during MS and EAE (Dendrou et al., 2015; Friese et al., 2014; 
Goverman, 2009) and the available therapeutics approved for the treatment of MS target 
inflammation (Haghikia et al., 2013; Wiendl et al., 2008). Although these therapeutics are 
successful in diminishing MS exacerbations in RRMS, they are often accompanied by side 
effects and especially the treatment strategies of SPMS and PPMS remain unsatisfying, 
demanding new insights into disease pathology. 
 
1.2) Disease pathogenesis and therapeutic treatment of MS 
The infiltration of active peripheral immune cells into the CNS is well defined during both MS 
and EAE (Dendrou et al., 2015; Friese et al., 2014; Goverman, 2009), and it was clearly shown 
in EAE that pathology is driven by myelin-specific T cells which need to be restimulated in 
the CNS to drive the disease (Kawakami et al., 2004; McMahon et al., 2005; Tompkins et al., 
2002). However, the reasons for the presence of active autoreactive adaptive immune cells 
causing MS in patients remain unknown. The activation of these autoreactive cells in the 
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lymph nodes is discussed to be based on molecular mimicry, the release of CNS antigen and 
bystander activation (Chastain and Miller, 2012; Fujinami et al., 2006; Guo and Janigro, 
2013). Of note, genetic and environmental factors can increase the MS risk (Belbasis et al., 
2015; Lill et al., 2015). 
Once activated, peripheral immune cells can cross the blood-brain barrier (BBB), which gets 
disrupted during the early phase of the disease, allowing infiltration into the immune 
privileged CNS. During the first wave of the disease, predominantly macrophages, B cells and 
CD8+ T cells as well as differentiated CD4+ Th1 and Th17 cells enter the CNS to cause 
inflammation and subsequently damage to oligodendrocytes and neurons (Dendrou et al., 
2015). While in the past Th1 cells were believed to be the main drivers of the disease, an 
additional pivotal role of Th17 became evident in the last decades (Lovett-Racke et al., 
2011). The skewing of T cell differentiation away from Th1 and Th17 towards a Th2 
phenotype is part of the effector mechanism of therapies making use of interferon (IFN)- 
(Kozovska et al., 1999), glatiramer acetate (Miller et al., 1998) and dimethyl fumarate (Gross 
et al., 2015). Beyond their impact on T cell differentiation, both CNS-infiltrating myeloid cells 
such as dendritic cells and macrophages, and microglia as the CNS-resident myeloid cells are 
discussed to cause re-activation of infiltrated T cells in the CNS, thus being vigorously 
involved in disease progression. The beneficial and detrimental properties of peripheral and 
CNS-resident myeloid cells in EAE and MS are presented in detail in the following sections. 
1.2.1) Myeloid cells during EAE and MS 
Myeloid cells are defined as cells which originate from a common myeloid progenitor cell, 
and thus include granulocytes and monocytes as well as dendritic cells, macrophages and 
microglia (Kawamoto and Minato, 2004; Ransohoff and Cardona, 2010) (Figure 2a). 
Interestingly, dendritic cells, macrophages and microglia do not only show common 
characteristics in the expression of surface molecules (Goldmann et al., 2013; Ponomarev et 
al., 2005), but in addition exhibit common functions like phagocytosis, antigen presentation 
and the secretion of pro- and anti-inflammatory mediators such as chemokines, cytokines 
and both neurotoxic and neurotrophic factors (s. 1.2.1.1-1.2.1.3 and Figure 2b). Although 
dendritic cells and macrophages are barely present in the healthy CNS, they are able to 
infiltrate the CNS parenchyma during MS and EAE after the disruption of the BBB (Bailey et 
al., 2007; Jiang et al., 2014; Lüssi et al., 2016). Thus, all these three distinct myeloid cell 
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subsets are able to impact the inflammatory milieu in the CNS during EAE and MS. In order 
to capture their beneficial and detrimental impacts on EAE disease, the entirety of dendritic 
cells, macrophages and microglia were further investigated in this study. 
1.2.1.1) Dendritic cells during EAE and MS 
In the steady state, dendritic cells predominantly reside in the periphery and only low 
numbers of dendritic cells are detectable in the CNS, where they are mainly located in 
vessel-rich areas both in humans and in mice (Lüssi et al., 2016; Prodinger et al., 2011). In 
the absence of inflammation, dendritic cells usually display an immature phenotype, 
characterized by low surface expressions of MHC-proteins and co-stimulatory molecules and 
by a high endocytic capacity, which quickly turns into an activated phenotype able to 
activate naïve T cells, upon interaction with microbial ligands or pro-inflammatory cytokines 
(Rescigno et al., 1998). Dendritic cells are commonly termed professional antigen presenting 
 
Figure 2: Schematic overview of the development and function of macrophages, dendritic cells and 
microglia. (a) Myeloid cells as macrophages, dendritic cells and microglia originate from a common myeloid 
progenitor cell. While microglia infiltrate the CNS only during development, macrophages and dendritic 
cells enter the CNS in adults if the blood-brain barrier (BBB) is disrupted. (b) Microglia, dendritic cells and 
macrophages show common functions, which could mediate detrimental (upper panel) and beneficial 
(lower panel) effects during inflammation. 
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cells (APC), due to their high capacity in stimulating and re-stimulating T cells (Sprent, 1995). 
After the phagocytic uptake of antigens, APC process the antigen proteins to small peptides, 
which are in the murine organism either presented on MHC-II molecules to stimulate CD4+ T 
cell activation, proliferation and differentiation, or on MHC-I molecules to stimulate CD8+ T 
cells (Germain and Margulies, 1993; Pennock et al., 2013). To prevent T cell anergy, the 
further upregulation of costimulatory molecules on APC is necessary (Harding et al., 1992). 
In EAE, CNS inflammation is associated with the recruitment of dendritic cells into the CNS 
(Bailey et al., 2007; Serafini et al., 2000). Comparably, dendritic cell accumulation has been 
reported in MS lesions (Serafini et al., 2006). Due to their high efficiency in antigen 
presentation and co-stimulation, dendritic cells were discussed to be pivotal during EAE and 
MS to (re-)stimulate pathogenic Th17 cells peripherally in the lymph nodes (de Vos et al., 
2002), but also in the target organ, the CNS (Bailey et al., 2007; Karman et al., 2006; 
Tompkins et al., 2002). In the animal model, it has been shown in vivo that CD11c+ dendritic 
cells were sufficient alone without the requirement of other MHC-II+ APC to present antigen 
in order to induce CNS inflammation (Greter et al., 2005). T cell (re-)stimulation and 
differentiation has been shown to be dependent on the cytokine profile secreted by 
dendritic cells (de Jong et al., 2005; Diebold, 2008; Fletcher et al., 2010). In this context, it 
has been shown that untreated MS patients harbor higher levels of dendritic cells that 
secrete pro-inflammatory cytokines such as IFN-γ, tumor necrosis factor (TNF)- and 
interleukin (IL)-23 compared to healthy controls (Huang et al., 1999; Vaknin-Dembinsky et 
al., 2006). Notably, the secretion of cytokines by dendritic cells varies not only between MS 
patients and healthy controls, but also between MS patients exhibiting different disease 
progressions. Whereas dendritic cells from RRMS patients could be described to induce both 
higher levels of Th1 cells and higher levels of Th2 cells compared to healthy controls, 
dendritic cells from SPMS patients only induced a polarized Th1 response, which was even 
elevated compared to the Th1 response in RRMS patients (Karni et al., 2006). Similarly, 
differences in the activation state of dendritic cells could be described comparing RRMS 
patients, SPMS patients and healthy controls, demonstrated by an altered expression of 
activation markers (Karni et al., 2006). These results indicate different roles of dendritic cells 
during different disease states. 
Recently, the relevance of dendritic cells in the mediation of CNS autoimmunity was further 
demonstrated, as they were found to strongly express the inflammatory chemokines Ccl5, 
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Cxcl9, and Cxcl10 and to function as gatekeepers in the CNS (Archambault et al., 2005; 
Paterka et al., 2016). In contrast, dendritic cells were also shown to be capable of promoting 
self-tolerance, which is predominantly mediated by the provision of central tolerance due to 
the thymic negative selection of autoreactive T cells (Brocker et al., 1997; Matzinger and 
Guerder, 1989) and by the stimulation of regulatory T cells, providing peripheral tolerance 
(Darrasse-Jèze et al., 2009; Steinman and Nussenzweig, 2002; Yogev et al., 2012). 
Consequently, the transfer of dendritic cells has been shown to mediate regulatory functions 
in EAE-diseased mice (Duraes et al., 2016; Legge et al., 2002; Li et al., 2008; Menges et al., 
2002), whereas the ablation of dendritic cells led to an increased disease course (Paterka et 
al., 2017). On the other hand, other studies could show that augmentation of dendritic cell 
numbers during EAE mediated an increase in EAE severity, and conversely, the depletion of 
dendritic cells was effective to decrease severity in adoptive transfer EAE (Greter et al., 
2005; Paterka et al., 2016). In summary, dendritic cells within the CNS and peripheral 
dendritic cells are pivotal for controlling the balance of encephalitogenic and regulatory T 
cells. Different dendritic cell subsets as well as the particular disease state seem to play a 
decisive role in the fate of these myeloid cells during the disease, but the gene expression 
profile which could be primarily responsible for the different dendritic cell fates remains 
elusive and was investigated in this work. 
1.2.1.2) Macrophages during EAE and MS 
Similar to dendritic cells, only few macrophages infiltrate the CNS under physiological 
conditions, while a massive infiltration of macrophages is detectable during EAE (Jiang et al., 
2014; Ousman and Kubes, 2012). A major function of macrophages includes the 
phagocytosis of apoptotic cells and pathogens (Martin et al., 2014). Their phagocytic activity 
can contribute to the clearance of apoptotic cells and myelin debris, which has been 
reported to be crucial to allow tissue regeneration during EAE (Bogie et al., 2011; Bruck et 
al., 1992; Neumann et al., 2009). Beside their phagocytic capacities, macrophages are able to 
contribute to disease progression by their release of pro- and anti-inflammatory mediators. 
On the one hand, they were shown to secret pro-inflammatory cytokines such as TNF-, IL-
12, IL-6 (Hendriks et al., 2005; Liu et al., 2013) and neurotoxic molecules such as reactive 
oxidative metabolites (Ding et al., 1988; Kigerl et al., 2009), on the other hand they are able 
to exert beneficial properties by the release of anti-inflammatory cytokines such as IL-10 (Liu 
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et al., 2013). In addition, similar to dendritic cells, macrophages are able to function as APC 
(Park et al., 2005), thus they are possibly contributing to T cell re-stimulation during EAE. 
Interestingly, neutralization of CCL22 activity has been shown to decrease macrophage 
accumulation in the CNS and was accompanied by a milder EAE course (Dogan et al., 2011), 
thus emphasizing the detrimental effects of macrophages during the disease. In the same 
sense it has been reported that the miRNA-mediated decrease in macrophage-activity 
inhibited EAE severity (Ponomarev et al., 2011). Cl2MDP-mnL treatment, which was 
described to transiently eliminate phagocytic macrophages from spleen, bone marrow and 
liver, but not dendritic cells, decreased clinical signs of EAE (Tran et al., 1998). By contrast, 
the injection of macrophages which were in vitro activated in the presence of opsonized 
sheep red blood cells prior to EAE induction, markedly protected mice from EAE 
development, thus highlighting their beneficial capacities (Tierney et al., 2009). The terms 
“M1” and “M2” macrophages are used in the literature to distinguish classically activated 
macrophages which exert pro-inflammatory functions and alternatively activated 
macrophages which exhibit anti-inflammatory properties, respectively (Franco and 
Fernández-Suárez, 2015; Jiang et al., 2014). 
1.2.1.3) Microglia during EAE and MS 
Microglia are the brain endogenous macrophages and are abundant both in the healthy and 
in the EAE- or MS-diseased CNS (Jiang et al., 2014; Ransohoff and Brown, 2012; Ransohoff 
and Perry, 2009). They are of myeloid origin and invade the CNS from the yolk sac during 
development, which has been demonstrated in mice (Ginhoux et al., 2010). These yolk sac-
derived microglia are maintained by self-renewal throughout the adult animal’s lifespan 
(Ajami et al., 2007; Hashimoto et al., 2013; Ransohoff, 2007). 
In the resting state, microglia continuously scan the brain parenchyma by prolonging and 
retracting their highly motile processes, allowing the screening of the whole CNS 
parenchyma within a few hours (Nimmerjahn et al., 2005). After acute damage, microglia 
polarize their motile processes in the direction of the damage origin, where they are able to 
respond to harmful intruders via the release of pro-inflammatory and other toxic agents, 
potentially resulting in detrimental effects (Lehnardt, 2010; Ransohoff and Brown, 2012). 
Besides astrocytes, microglia are the main source of neurotoxic inflammatory mediators 
such as cytokines, chemokines and reactive oxygen species that promote neurodegeneration 
(Hanisch, 2002; Heneka et al., 2014). However, microglia as the CNS-resident immune cells, 
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are not only required to form the first line of defense against invading pathogens, but also to 
maintain brain homeostasis. In addition to their expression of inflammatory mediators, they 
also express neurotrophic and immunosuppressive factors, favoring tissue regeneration 
(Heneka et al., 2014; Kabba et al., 2017). The regeneration favoring state of microglia was 
discussed recently to be classified as an M2 phenotype, comparable to anti-inflammatory 
M2 macrophages in the periphery (Franco and Fernández-Suárez, 2015). Although this 
nomination is controversially discussed, the capacity of microglia to promote tissue repair is 
well accepted (Ransohoff, 2016). Microglial displacement of inhibitory synapses has been 
shown to provide neuroprotection in the adult brain (Chen et al., 2014). Analogous to 
macrophages in the periphery, microglia also act as professional phagocytes in the CNS, 
thereby enabling the clearance of dead material (Sierra et al., 2013). 
During neuroinflammatory diseases, such as EAE and MS, microglia are likely involved in the 
re-stimulation and thus the activation of infiltrating pathogenic T cells, mediated by the 
microglial ability to act as APC (Aloisi et al., 1999; Carson, 2002). Antigen presentation by 
microglia via MHC-I has been clearly demonstrated, while antigen presentation via MHC-II in 
vivo is still a matter of debate (Korn and Kallies, 2017). In addition to their function in 
antigen presentation, detrimental microglial effects can be mediated via the creation of a 
cytotoxic inflammatory milieu that induces bystander damage contributing to lesion 
pathogenesis (Merson et al., 2010). The microglial activation can thereby result among other 
activators from oligodendrocyte-damage, myelin-damage or axonal damage (Merson et al., 
2010). Inflammation-associated oxidative burst in activated microglia and macrophages is 
important during demyelination and during free radical-mediated tissue injury in the 
pathogenesis of MS (Fischer et al., 2012; Takeuchi et al., 2006). The decisive role of 
microglial activation in the disease becomes evident as it has been described to be a 
hallmark of demyelinating lesions in EAE (Ponomarev et al., 2005) and microglial activity in 
the cortical grey matter of living MS-diseased individuals corresponded with progression of 
disability (Politis et al., 2012). Furthermore, another study showed that cortical 
demyelination and diffuse axonal injury in normal-appearing white matter was associated 
with profound microglial activation (Kutzelnigg, 2005). Markers of both classically (M1) and 
alternatively (M2) activated macrophages could be identified among microglia present in 
microglia nodules in the CNS of MS patients (Singh et al., 2013). 
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The relevance of microglia is further emphasized by targeting them during the disease. The 
microglia-specific depletion of the kinase TAK1 was efficient to drastically decrease EAE 
(Goldmann et al., 2013), pointing to the essential ability of these cells to drive the disease. Of 
note, microglia were very specifically targeted in this model using a tamoxifen-inducible 
CX3CR1CreER system and thereby excluding the effect of other myeloid cells from 
contributing to the decreased disease course after TAK1 depletion. Other studies confirmed 
the indispensable role of microglia during EAE, reflected by an attenuated disease course 
after microglia paralysis (Heppner et al., 2005). Pharmacological treatment with macrophage 
inhibitory factor or minocycline, which target microglia, drastically decreased EAE severity, 
pointing to the essential impact of these cells on the development of the disease (Bhasin et 
al., 2007; Popovic et al., 2002). 
Interestingly, analogously to the ambivalent effects of dendritic cells and macrophages 
during the disease, beneficial roles of microglia were described in addition to their 
detrimental properties during EAE and MS (Kerschensteiner et al., 2003). Microglia are able 
to secret anti-inflammatory cytokines such as IL-10 and IL-4 (Lobo-Silva et al., 2017; 
Ponomarev et al., 2007), which are beneficial for the disease outcome. IL-4 has been 
described to favor the protective potential of microglial cells during MS (Napoli and 
Neumann, 2010). Both IL-4- and IL-10-deficiency in mice yielded aggravated EAE courses 
(Bettelli et al., 1998; Falcone et al., 1998). Thereby, CNS-derived IL-4 seems to play a major 
role compared to peripheral IL-4 in order to mediate beneficial effects (Ponomarev et al., 
2007). Beyond cytokine secretion, the beneficial effect of microglia is mediated by their 
phagocytic capacity, which has not only been found to be important in the resting state, but 
also to be beneficial in EAE, where significant clearance of cell debris and dead or apoptotic 
cells promotes the regeneration process in the CNS and reduces inflammation (Kotter, 2006; 
Lampron et al., 2015; Neumann et al., 2009; Olah et al., 2012; Sierra et al., 2013; Yamasaki et 
al., 2014). The triggering receptor expressed on myeloid cells 2 (TREM2) is expressed on 
microglia and its overexpression on myeloid cells has been shown to ameliorate EAE disease 
severity via the promotion of phagocytosis (Takahashi et al., 2007). 
In summary, similarly to dendritic cells and macrophages, both beneficial and detrimental 
roles of microglia have been described during EAE and MS and inhibition of neurotoxic 
properties of microglia is likely to be a useful therapeutic strategy in MS. 
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1.2.2 Therapeutics targeting myeloid cells in MS 
In addition to therapeutic treatment strategies which target the infiltration and activation of 
lymphocytes, many therapeutic treatments of MS directly target myeloid cells, further 
emphasizing their essential role during the disease (Figure 3). As mentioned above, the 
skewing of T cell differentiation away from Th1 and Th17 towards a Th2 phenotype is part of 
the effect mechanism of therapies making use of IFN- (Kozovska et al., 1999), glatiramer 
acetate (Miller et al., 1998) and dimethyl fumarate (Gross et al., 2015). The IFN--dependent 
skewing away from a Th17 phenotype is likely to be mediated by a direct effect on APC. In 
this sense, IFN- has been shown to alter the expression of cytokines and co-stimulatory 
molecules in myeloid cells isolated from MS patients and healthy controls (Huang et al., 
1999; Marckmann et al., 2004; Ramgolam et al., 2009). Glatiramer acetate also directly 
affects myeloid cells, inducing a regulatory phenotype of these cells (Kim et al., 2004). 
Comparably, fingolimod and fumarate therapies improve MS by inducing an anti-
inflammatory cell phenotype (Ghoreschi et al., 2011; Hughes et al., 2008). Strikingly, 
dimethyl fumarate showed the capacity to inhibit the production of nitric oxide and pro-
inflammatory cytokines in microglial cells (Wilms et al., 2010). In this context, Laquinimod 
has been shown to exhibit a regulatory effect, which is mediated by the NF-kB pathway on 
 
Figure 3: Targets of therapeutics effecting myeloid cells. The role of dendritic cells, macrophages and 
microglia in the pathogenesis of EAE and MS is shown. The therapeutics which affect these myeloid cells 
and myeloid cell functions are highlighted in green. 
BEATRICE WASSER  INTRODUCTION 
20 
 
murine and human myeloid cells and impacts the cytokine and chemokine pattern of these 
cells (Jolivel et al., 2013). Daclizumab has been also described to target myeloid APC, as it is 
not only able to bind CD25 on T cells, but also to potently inhibit IL-2 trans-presentation 
during APC-mediated T cell activation (Wuest et al., 2011). Altogether, myeloid cells seem to 
be substantially involved in EAE and MS. Although the mentioned available therapeutics 
partly target myeloid cells, their effect mechanisms are rather broad and often accompanied 
by side effects. Thus, it would be preferable to identify mechanisms which are responsible 
for the different effects of myeloid cells during the disease and which could reveal more 
specific targets for new therapeutics. 
 
1.3) Aims and strategies 
As described above, myeloid cells fulfill various roles during EAE and MS, among them both 
beneficial and detrimental effects. To gain deeper insight into the functional roles of myeloid 
cells in disease exacerbation and regeneration processes and to determine which specific 
molecular mediators are responsible for these distinct roles of the myeloid cells, two major 
strategies were followed in this thesis. 
First, highly pure CD11c+ myeloid cells were isolated during distinct disease states using 
fluorescence activated cell sorting (FACS). The surface molecule CD11c was chosen for 
positive selection to include dendritic cells, but also activated microglia and macrophages, 
which upregulate the expression of the dendritic cell marker CD11c upon activation 
(Ponomarev et al., 2005) for further analysis. The isolated CD11c+ myeloid cells were used 
for deep RNA sequencing to determine differentially expressed genes over the disease 
course. The up- or downregulation of gene expression in decisive disease stages would 
indicate a crucial role of the regulated genes during the corresponding disease stage, 
uncovering their impact on the disease progression and thus potentially revealing a new 
therapeutic target molecule in EAE and MS. 
In addition to genetic approaches, direct interactions between pathogenic T cells and 
microglia, the most abundant myeloid cell population in the CNS, were evaluated in living 
EAE-diseased mice during the disease as well as in organotypic hippocampal slices using two-
photon microscopy, in order to directly investigate the role of microglia upon Th17 attack. 
Even though the understanding of the complex balance between detrimental and beneficial 
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roles of microglia during EAE and MS is essential, live interaction between microglial cells 
and other immune cells such as T cells in the CNS in vivo has not been demonstrated in detail 
yet.
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2)  Materials and Methods 
2.1) Materials 
2.1.1) Instruments 
Instrument Company 
Autoclave Heraeus Thermo Fisher Scientific, Waltham (USA) 
Analog Vortex Mixer VWR International GmbH, Darmstadt (Germany) 
BD FACS Canto II BD Bioscience, Franklin Lakes (USA) 
BD FACS Aria II BD Bioscience, Franklin Lakes (USA) 
Bioanalyzer 2100  Agilent, Santa Clara (USA) 
Bioanlayzer Chip Vortexer (IKA MS 3) Agilent, Santa Clara (USA) 
Cell Counting Chamber Neubauer improved Brand , Wertheim (Germany) 
Cell Culture Incubator Binder GmbH, Tuttlingen (Germany) 
Cell Culture Microscope, bright field Hund, Wetzlar (Germany) 
Centrifuge Heraeus Fresco 21 Thermo Fisher Scientific, Waltham (USA) 
Centrifuge Multifuge Heraeus XIR Thermo Fisher Scientific, Waltham (USA) 
CFX Connect™ Real Time Detection System Bio-Rad Laboratories, München (Germany) 
Confocal Laser Scanning System SP8 Leica GmbH, Wetzlar (Germany) 
Eppendorf Research Adjustable-volume 
Pipettes 
Eppendorf GmbH, Wesseling-Berzdorf 
(Germany) 
Fridges and Freezers Liebherr, Bulle (Switzerland) 
Freezer (Sanyo) 
EWALD Innovationstechnik GmbH, Rodenberg 
(Germany) 
Gamma irradiator Gammacell 2000 Mølsgaard Medical, Risø (Denmark) 
Horizontal Laminar Flow Hood Heraguard Thermo Fisher Scientific, Waltham (USA) 
Magnetic Stand Ambion Thermo Fisher Scientific, Waltham (USA) 
McILWAIN tissue chopper 
Campden Instruments LTD, Loughborough 
(England) 
MidiMACS and QuadroMACS Separators 
Miltenyi Biotec GmbH,  
Bergisch Gladbach (Germany) 
MiSeq System Ilumina, San Diego (USA) 
NanoDrop 2000c Thermo Fisher Scientific, Waltham (USA) 
Pipetus 
Hirschmann Laborgeräte GmbH & Co.KG, 
Eberstadt (Germany) 
Platform Shaker Edmund Bühler GmbH, Hechingen (Germany) 
Qubit® 2.0 Fluorometer Thermo Fisher Scientific, Waltham (USA) 
Surgery Instruments Fine Science Tools Inc., Heidelberg (Germany) 
TC10TM automated cell counter 
Bio-Rad Laboratories GmbH, München 
(Germany) 
Thermal Cycler Peqlab GmbH, Erlangen (Germany) 
Vertical Laminar Flow Hood SAFE 2020 Thermo Fisher Scientific, Waltham (USA) 
Vibratome Microm HM650V Thermo Fisher Scientific, Waltham (USA) 
Water bath Aqualine AL18 
Lauda GmbH & CO. KG, Lauda-Königshofen 
(Germany) 
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2.1.1.1) Two-photon Laser Scanning Microscopy (TPLSM) System 
Instrument Company 
Bold-Line series of stage top incubators Okolab, Pozzuoli (Italy) 
Leica HCX IRAPO L 25x/0.95 W objective Leica GmbH, Wetzlar (Germany) 
Leica TCS-MP5 multi-photon system Leica GmbH, Wetzlar (Germany) 
MaiTai Laser (Ti:Sa) Spectra Physics, Irvine (USA) 
Olympus BX51 WI upright microscope fitted 
with an Olympus XLUMPlanFI 20x/0.95 W 
objective 
Olympus Soft Imaging Solutions GmbH, Münster 
(Germany) 
Optical Parametric Oscillator (OPO) APE, Berlin (Germany) 
TriMScope I 2-photon microscope La Vision BioTec GmbH, Bielefeld (Germany) 
 
2.1.2) Laboratory Supplies, Plastics and Glassware 
Product Company 
Cell Counting Slides for TC10™/TC20™ Cell 
Counter, Dual-Chamber 
Bio-Rad Laboratories GmbH, München 
(Germany) 
Cell Culture Dish, polystyrene, Ø 60 mm + 
100 mm 
Greiner Bio-One GmbH, Frickenhausen 
(Germany) 
Cell Culture Flask, 75 cm2  
Greiner Bio-One GmbH, Frickenhausen 
(Germany) 
Cell strainer, nylon mesh, 100 µm BD Bioscience, Franklin Lakes (USA) 
Centrifuge Tubes, polypropylene (PP), 15 mL + 
50 mL 
Greiner Bio-One GmbH, Frickenhausen 
(Germany) 
 
Cling film Carl Roth GmbH, Karlsruhe (Germany) 
Eppendorf Tubes 1.5 mL + 2 mL 
Eppendorf GmbH, Wesseling-Berzdorf 
(Germany) 
Hypodermic Needle 20G + 27G BD Microlance, Gateshead (UK) 
MACS LS Columns 
Miltenyi Biotec GmbH,  Bergisch Gladbach 
(Germany) 
Microscope glass slides Thermo Fisher Scientific Inc., Waltham (USA) 
Millicell cell culture insert, 30 mm, 0,4 µm Merck Millipore, Darmstadt (Germany) 
Multiplate PCR Plates, 96 Wells, clear 
Bio-Rad Laboratories GmbH, München 
(Germany) 
Multiwell Plate, tissue-culture treated 
polystyrene, 24-well, 48-well, 96-well 
BD Bioscience, Franklin Lakes (USA) 
Netwell insert, 15 mm, mesh size 74 µm Sigma-Aldrich Corp., St Louis (USA) 
Pipette tips 10 µL, 200 µL, 1000 µL VWR International GmbH, Darmstadt (Germany) 
Filter pipette tips 10 µL, 200 µL, 1000 µL Starlab, Hamburg (Germany) 
Polystyrene Round Bottom Test Tubes 5 mL 
(FACS tubes) 
BD Bioscience, Franklin Lakes (USA) 
Qubit™ Assay Tubes Thermo Fisher Scientific, Waltham (USA) 
Pre-Separation Filters, 30 µm 
Miltenyi Biotec GmbH, Bergisch Gladbach 
(Germany) 
Scalpels B. Braun AG, Melsungen (Deutschland) 
Serological Pipettes, polystyrene, 5 mL + 10 mL 
+ 25 mL 
Greiner Bio-One GmbH, Frickenhausen 
(Germany) 
Syringe, 1 mL + 2 mL + 30 mL B. Braun AG, Melsungen (Deutschland) 
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2.1.3) Chemicals and Reagents 
Compound Company 
Albumin bovine, cell culture grade (BSA) Serva Electrophoresis, Heidelberg (Germany) 
Ammonium chloride (NH4Cl) Sigma-Aldrich Corp., St Louis (USA) 
Ampure XP beads Beckman Coulter, Krefeld (Germany) 
Annexin V Biolegend, San Diego (USA) 
Aqua bi. dest. Sterile B. Braun AG, Melsungen (Germany) 
Basal Medium Eagle (BME) Thermo Fisher Scientific, Waltham (USA) 
Betaine Sigma-Aldrich Corp., St Louis (USA) 
Brefeldin A Sigma-Aldrich Corp., St Louis (USA) 
Collagenase R&D Systems, Inc., Minneapolis (USA) 
Dexamethasone Sigma-Aldrich Corp., St Louis (USA) 
4,6-diamidino-2phenylindole, dihydrochloride 
(DAPI) 
Thermo Fisher Scientific, Waltham (USA) 
D-Glucose Carl Roth GmbH, Karlsruhe (Germany) 
Dispase R&D Systems, Inc., Minneapolis (USA) 
DNase I F. Hoffmann-La Roche AG, Basel 
dNTP mix (10 mM each) Thermo Fisher Scientific, Waltham (USA) 
Dulbeccos PBS with Ca2+ & Mg2+ Gentaur, Kampenhout (Belgium) 
EB solution Qiagen, Hilden (Germany) 
Ethanol 100 % (v/v) (EtOH) AppliChem GmbH, Darmstadt (Germany) 
Ethanol 70 % (v/v) (EtOH) AppliChem GmbH, Darmstadt (Germany) 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH, Karlsruhe (Germany) 
EDTA disodium salt dehydrate (Na2EDTA) 
solution (0.5 M) 
Sigma-Aldrich Corp., St Louis (USA) 
Fetal Bovine Serum, heat inactivated (FBS)(FCS) Biochrom AG, Berlin (Germany) 
HEPES Life Technologies Corp., Grand Island (USA) 
Horse Serum, heat inactivated Thermo Fisher Scientific, Waltham (USA) 
IMDM Life Technologies Corp., Grand Island (USA) 
Isoflurane Abbot, Wiesbaden (Germany) 
IS PCR oligo (5′-AAGCAGTGGTATCAACGCAGAGT-3′) biomers.net GmbH, Ulm (Germany) 
iQ™ SYBR® Green Supermix Bio-Rad Laboratories, München (Germany) 
KAPA HiFi HotStart ReadyMix (2×) KAPA Biosystems, Wilmington (USA) 
Ketamine Hameln Pharma Plus GmbH, Hameln (Germany) 
L-Glutamine (200 mM) Sigma-Aldrich Corp., St Louis (USA) 
Lipopolysaccharide (LPS) Enzo Life Sciences GmbH, Lörrach (Germany) 
Magnesium chloride (MgCl2 ) Sigma-Aldrich Corp., St Louis (USA) 
M-CSF Peprotech, Rocky Hill (USA) 
Minimum Essential Medium (MEM) Thermo Fisher Scientific, Waltham (USA) 
NaCl solution 0.9 % B. Braun AG, Melsungen (Germany) 
N-Acetyl-D-Glucosamine (GlcNAc) Sigma-Aldrich Corp., St Louis (USA) 
Normal goat serum (NGS) Vector Laboratories, Burlingame (USA) 
Oligo-dT Primer 
(5′–AAGCAGTGGTATCAACGCAGAGTACT30VN-3′, where 
‘N’ is any base and ‘V’ is either A, C or G) 
biomers.net GmbH, Ulm (Germany) 
Paraformaldehyde (PFA) Carl Roth GmbH, Karlsruhe (Germany) 
Penicillin / Streptomycin (P/S) (10,000 units 
penicillin and 10 mg streptomycin per mL) 
Sigma-Aldrich Corp., St Louis (USA) 
Percoll Sigma-Aldrich Corp., St Louis (USA) 
Potassium bicarbonate Sigma-Aldrich Corp., St Louis (USA) 
ProLong Gold Antifade Mountant Thermo Fisher Scientific, Waltham (USA) 
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Propidium iodide (PI) Sigma-Aldrich Corp., St Louis (USA) 
RNAse inhibitor Clontech, Mountain View (USA) 
Rompun 2 % injection solution (Xylazin) Bayer Health Care, Leverkusen (Germany) 
RPMI 1640 Life Technologies Corp., Grand Island (USA) 
Saponine Carl Roth GmbH & Co. KG, Karlsruhe (Germany) 
Sodium bicarbonate (NaHCO3) Carl Roth GmbH & Co. KG, Karlsruhe (Germany) 
Triton X-100 Sigma-Aldrich Corp., St Louis (USA) 
Trypan blue Sigma-Aldrich Corp., St Louis (USA) 
TSO (5′-AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3′) Exiqon, Vedbaek (Denmark) 
Wortmannin Sigma-Aldrich Corp., St Louis (USA) 
β-Mercaptoethanol Sigma-Aldrich Corp., St Louis (USA) 
 
2.1.4) Kits 
Kit Company 
CD4 T Cell Isolation Kit Miltenyi Biotec GmbH, Bergisch Gladbach 
(Germany) 
DNase I recombinant, RNase free with 10x 
Incubation buffer  
F. Hoffmann-La Roche AG, Basel 
Hooke Kit™ MOG35-55/CFA Emulsion + PTX Hooke Laboratories, Inc. 
Lawrence (USA) 
Hooke Kit™ PLP139-151/CFA Emulsion + PTX Hooke Laboratories, Inc. 
Lawrence (USA) 
High Sensitivity DNA kit Agilent, Santa Clara (USA) 
Image-iT® LIVE Red Caspase-3 and -7 detection 
kit 
Thermo Fisher Scientific, Waltham (USA) 
MiSeq Reagent Kit v3 Ilumina, San Diego (USA) 
Nextera xt DNA library preparation kit Ilumina, San Diego (USA) 
RNA 6000 Pico kit Agilent, Santa Clara (USA) 
RNeasy® Micro Kit Qiagen, Hilden (Germany) 
RNeasy® Mini Kit Qiagen, Hilden (Germany) 
Superscript II reverse transcriptase + 
Superscript II First strand buffer + DTT 
Thermo Fisher Scientific, Waltham (USA) 
Superscript III First Strand Synthesis System  Thermo Fisher Scientific, Waltham (USA) 
Qubit RNA assay kit Thermo Fisher Scientific, Waltham (USA) 
Qubit dsDNA HS assay kit Thermo Fisher Scientific, Waltham (USA) 
 
2.1.5) Microbeads 
Kit Isotype Company 
CD8a (Ly-2) MicroBeads mouse-α-mouse monoclonal IgG2a Miltenyi Biotec GmbH,  
Bergisch Gladbach (Germany) 
CD11c MicroBeads hamster-α-mouse monoclonal 
antimouse IgG 
Miltenyi Biotec GmbH,  
Bergisch Gladbach (Germany) 
CD62L MicroBeads rat-α-mouse monoclonal IgG2a Miltenyi Biotec GmbH,  
Bergisch Gladbach (Germany) 
CD90.2 MicroBeads rat-α-mouse monoclonal IgG2b Miltenyi Biotec GmbH,  
Bergisch Gladbach (Germany) 
 
BEATRICE WASSER  MATERIALS AND METHODS 
26 
 
2.1.6) Cytokines 
Cytokines Company 
huTGF-β R&D Systems, Inc., Minneapolis (USA) 
IL-2 R&D Systems, Inc., Minneapolis (USA) 
IL-23 R&D Systems, Inc., Minneapolis (USA) 
IL-4 R&D Systems, Inc., Minneapolis (USA) 
IL-6 R&D Systems, Inc., Minneapolis (USA) 
 
2.1.7) Custom Buffers, Solutions and Media 
Buffer/Solution Ingredients 
Anesthesia solution 20 mL 50 mg/mL Ketamine 
2.5 mL 2% Rompun 
in 77.5 mL 0.9 % NaCl solution 
FACS Buffer 0.5 % BSA  
in PBS 
Lysis Buffer 8.29 g/L NH4Cl 
1 g/L KHCO3  
37.2 mg/L NA2EDTA  
in dH2O 
MACS Buffer 0.5 % BSA 
0.5 M EDTA 
in PBS 
MEM (2x) 160.93 g MEM  
+ 0.35 g NaHCO3 
+ 5 L Aqua dest. 
Paraformaldehyde (PFA) buffer 4 % 40 g Paraformaldehyde 
+ 1000 mL 0.1 M PBS buffer, pH 7.0 – 7.4 
Phosphate buffer (PB) 810 mL of 35.6 g/L di-Sodium hydrogenpohphate 
dihydrate 
+190 mL of 31.2g/L Sodium 
dihydrogenphosphate dihydrate 
+ 1L H2O 
pH 7.35-7.4 
Saponine Buffer 0.5 % Saponine 
0.5 % BSA 
in PBS 
 
Media Ingredients 
Mouse Medium (MM) 10 % FCS 
1 % P/S 
1 % L-Glutamine 
0.1 % β-Mercaptoethanol 
1 % HEPES 
in RPMI  
Wash Medium (WM) 5 % FCS 
1 % P/S 
1 % HEPES 
in RPMI 
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Slice culture Medium 50 mL 2x MEM 
+ 41.8 mL Aqua dest. Sterile 
+ 50 mL BME 
+ 50 mL heat inactivated horse serum 
+ 2 mL 200 mM L-Glutamine 
+ 6.25 mL 20 % Glucose 
pH 7.2 
Slice preparation medium 100 mL 2x MEM 
+ 98 mL Aqua dest. Sterile 
+ 1 mL 200 mM L-Glutamine 
pH 7.35 
 
 
2.1.8) Antibodies 
Antibody Clone Isotype Concentration Company 
αCD11c-APC HL3 hamster-α-mouse 
monoclonal IgG1, λ2 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD16/ αCD32 
(FC-block)  
2.4G2 rat-α-mouse 
monoclonal IgG2b, κ 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD206-BV421 
 
CO68C2 rat-α-mouse 
monoclonal IgG2a, κ 
0.12 mg/mL Biolegend, San Diego 
(USA) 
αCD25-APC 
 
PC61 rat-α-mouse 
monoclonal IgG1, λ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD28 
 
H57-597 hamster-α-mouse 
monoclonal IgG2, λ1 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD3-APC  
 
1452-C11 hamster-α-mouse 
monoclonal IgG1, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD3e 
 
1452-C11 hamster-α-mouse 
monoclonal IgG1, κ 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD45-
eFluor605 
30-F11 rat-α-mouse 
polyclonal IgG 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD45-FITC 30-F11 rat-α-mouse 
polyclonal IgG2b κ 
0.5 mg/mL Thermo Fisher 
Scientific, Waltham 
(USA) 
αCD45.1-PE A20 mouse-α-mouse 
monoclonal IgG2a, κ 
0.2 mg/mL Biolegend, San Diego 
(USA) 
αCD4-AF647 
 
RM4-5 rat-α-mouse 
monoclonal IgG2a 
0.1 mg/mL Life Technologies 
Corp., Grand Island 
(USA) 
αCD4-Horizon 
(V450) 
RM4-5 rat-α-mouse 
monoclonal IgG2a, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD4-PECy7 
 
RM4-5 rat-α-mouse 
polyclonal IgG 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD44-AF700 IM7 rat-α-mouse 
monoclonal IgG2b, κ 
0.2 mg/mL Thermo Fisher 
Scientific, Waltham 
(USA) 
αCD62L-APC 
 
MEL-14 rat-α-mouse 
monoclonal IgG2a, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αCD90.2-Pacific 53-2.1 rat-α-mouse 0.5 mg/mL Biolegend, San Diego 
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Blue monoclonal IgG2a, κ (USA) 
αGFP polyclonal rabbit polyclonal IgG  5 mg/mL Abcam, Cambridge 
(UK) 
αI-A[b]-PE AF6-120.1 mouse-α-mouse 
monoclonal IgG2a, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αI-A[K]-FITC 10-3.6 mouse-α-mouse 
monoclonal IgG2a, κ 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αIFN-γ 
 
XMG1.2 rat-α-mouse 
monoclonal IgG1 
8.25 mg/mL BioXCell, West 
Lebanon (USA) 
αIFN-γ-Horizon 
(V450) 
XMG1.2 rat-α-mouse 
monoclonal IgG1, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αIL-10-APC JES5-16E3 rat-α-mouse 
monoclonal IgG 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αIL-12 
 
C17.8 rat-α-mouse 
monoclonal IgG2a 
7.48 mg/mL BioXCell, West 
Lebanon (USA) 
αIL-17A-APC 
 
eBio17B7 rat-α-mouse 
monoclonal IgG2a, κ 
0.2 mg/mL Thermo Fisher 
Scientific, Waltham 
(USA) 
α-rabbit-AF488 polyclonal goat-α-rabbit 
polyclonal IgG 
2 mg/mL Thermo Fisher 
Scientific, Waltham 
(USA) 
αTNF-α-AF700 MP6-XT22 rat-α-mouse 
monoclonal IgG1, κ 
0.2 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
αVβ11-FITC RR3-15 rat-α-mouse 
monoclonal IgG2b, κ 
0.5 mg/mL BD Bioscience, Franklin 
Lakes (USA) 
 
2.1.9) qRT-PCR Primers 
Gene Fw Sequence Rev Sequence Concentration Tm 
[°C] 
murine ß-actin AATCTTCCGCCTTAATACT AGCCTTCATACATCAAGT 100 nM 59  
murine Arginase-1 AAGGTCTCTACATCACAGAA GAAGCAAGCCAAGGTTAA 200 nM 60 
murine Ms4a8a AGATAAGTGAACCTGAAGATT GTGAGTTGAAGCAAGAGT 400 nM 58 
murine Ym1 GACTATGAAGCATTGAAT TCTGATAACTGACTGAAT 400 nM 54 
 
2.1.10) Mice 
2.1.10.1) Wildtype Mice 
Strain Laboratory 
C57BL/6 (B6) Janvier Labs, Laval (France) 
SJL/J Janvier Labs, Laval (France) 
 
2.1.10.2) Genetically modified mice 
Strain Target Properties Reference/In house breeding 
B6.2D2 CD4+ T cells are MOG35–55 specific (Bettelli et al., 2003) 
B6.2D2.CFP CD4+ T cells are MOG35–55 specific and 
labeled in blue 
B6.2D2 x B6.CRFP 
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B6.2D2.RFP CD4+ T cells are MOG35–55 specific and 
labeled in red 
B6.2D2 x B6.acRFP 
B6.CFP ubiquitous CPF expression, thus cells 
are labeled in blue 
CK6/ECFP (Hadjantonakis et 
al., 2002) 
back-crossed to C57BL/6  
B6.acRFP ubiquitous RPF expression, thus cells 
are labeled in red 
(Luche et al., 2007) 
B6.CX3CR1.GFP CX3CR1+ Microglia are labeled in green (Jung et al., 2000) 
B6.Rag1-/- Mice lack T and B cells (Mombaerts et al., 1992) 
B6.Rag1-/-.CX3CR1.GFP B6.CX3CR1.GFP and CX3CR1+ Microglia 
are labelled in green 
B6.CX3CR1.GFP x B6.Rag1-/- 
 
2.1.11) Software 
Software Application Company 
2100 expert software Analysis of data assessed 
with the Bioanalyzer 2100 
Agilent, Santa Clara (USA) 
Beacon Designer 8 Software Primer design Premier Biosoft International, 
Palo Alto (USA) 
Bioconductor (R) (v3.2.0) with  
Bioconductor (R) packages 
DESeq (v1.2) and EdgeR (v3.10) 
Statistical analysis of RNA-
Seq data 
Bioconductor 
(Anders and Huber, 2010) 
(Robinson et al., 2009) 
Bio-Rad CFX Manager Assessment of qRT-PCR data Bio-Rad Laboratories, München 
(Germany) 
CLC Genomic Workbench 7.0 Assessment of RNA-Seq data Qiagen, Hilden (Germany) 
FACSDiva FACS Analysis BD Bioscience, Franklin Lakes 
(USA) 
FlowJo FACS Analysis Tree Star, Ashland (USA) 
GraphPad Prism 6 Statistical Analysis GraphPad Software, Inc., La 
Jolla (USA) 
ImageJ Analysis of histological 
stainings 
National Institutes of Health, 
Bethesda (USA) 
Imaris (v. 8.1.2) Analysis and Video 
preparation of  two-photon 
images 
Bitplane AG, Zurich 
(Switzerland) 
NanoDrop 2000 / 2000c 
Operating Software 
Determination of RNA 
concentrations 
Thermo Fisher Scientific, 
Waltham (USA) 
Office 2007/2010 Text preperations, 
Calculations, 
Figure preparations  
Microsoft Corp., Redmond 
(USA) 
 
 
2.2) Methods 
2.2.1) Handling of cell culture 
All cell culture experiments were handled under a laminar flow hood under sterile 
conditions. The materials for cell culturing were sterilized or disinfected with 70 % ethanol 
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before use. Waste was autoclaved at 121 °C for 20 min at 1 bar. Cells were cultured at 37 °C 
in a 5 % CO2 atmosphere and 95 % humidity, as enabled by the use of cell culture incubators.  
2.2.2) Cell counting 
Cells were counted either manually (2.2.2.1) or with the help of a Bio-Rad cell counter 
(2.2.2.2). 
2.2.2.1) Manual cell counting 
Cells were taken up in a defined volume and an aliquot of the cell suspension was mixed 
with trypan blue in a ratio of 1:2, 1:5 or 1:10, depending on the expected cell count. The 
mixture was applied to a Neubauer counting chamber. The cells of the four quadrants of the 
chamber were counted under a light microscope and divided by four to evaluate the cell 
number of one quadrant. Trypan blue traverses only through the damaged cell membrane of 
dead cells, and not through the intact cell membrane of living cells and therefore allows the 
visual differentiation between living (colorless) and dead (blue) cells (Strober, 2001). The 
total number of living cells was calculated according to the following formula: 
Total cell number = counted cells/quadrant x 104 (chamber coefficient) x dilution factor (in 
trypan blue) x volume cell suspension 
2.2.2.2) Counting with Biorad cell counter 
Cells were taken up in a defined volume and an aliquot of the cell suspension was mixed 
with trypan blue in a ratio of 1:2. The mixture was applied to a Bio-Rad counting chamber. 
The Bio-Rad counting chamber was transferred into the Bio-Rad cell counter and automatic 
cell counting was started. The Bio-Rad cell counter provided the concentration of total and 
living cells per milliliter cell suspension. To determine the absolute cell count, the 
concentration was multiplied by the volume of cell suspension. 
2.2.3) Magnetic activated cell sorting (MACS) 
MACS allows the separation of distinct cell populations depending on their surface antigens 
(Miltenyi et al., 1990). This method takes advantage of antibodies tagged with magnetic 
beads in order to magnetically label distinct surface molecules and therefore to label specific 
cells populations. For the MACS mediated separation of distinct cell populations, kits from 
Miltenyi Biotec were used according to the manufacturer’s instructions if not otherwise 
described. Cells were incubated with the appropriate magnetically labeled antibodies for 5-
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15 minutes (depending on the surface antigens) at 4 °C in MACS buffer. Subsequently, 35 mL 
MACS buffer was added to wash the cell suspension and to remove the remaining magnetic 
beads. Cells were centrifuged (5 min, 550 g, 4 °C) and the cell pellet was resuspended in 
1 mL of MACS buffer per 3x108 cells. The cell suspension was then transferred through a pre-
separation filter (30 µm) onto a pre-rinsed MACS column in the magnetic field of a MACS 
separator. To pre-rinse the MACS column, 3 mL of MACS buffer were applied on the column. 
The nylon mesh was used to avoid clustering of cells and plugging of the column. A 
maximum of 3x108 cells were added on one MACS column to ensure highest efficiencies of 
the sorts. After transferring the labeled cells onto the MACS column with a 1 mL-pipet, the 
pipet tip was rinsed in an Eppendorf tube containing 1 mL of MACS buffer to collect cells for 
a purity check of the sort (“pre MACS sample”). Once the cell suspension was completely 
infiltrated into the column, the column was washed three times, each with 3 mL MACS 
buffer. To prevent the loss of cells in the original tube, the first two washing steps were 
performed with MACS buffer, which was at the same time used to rinse the original tube. 
The third washing step was performed with pure MACS buffer. Thus, the rinsed column 
contained only the magnetically labeled target cells within its magnetic field. Depending on 
the sorting strategy, either the labeled cell fraction in the magnetic field (positive sort) or the 
unlabeled cells in the flow-through (negative sort, untouched) were used for further 
experiments. Since negative sorts usually require a variety of different antibodies to exclude 
all non-target cells, it is common to use a mixture of biotinylated antibodies for those 
negative sorts prior to the labeling of these antibodies with anti-biotin antibodies coupled to 
magnetic beads. After the negative sort, the flow though contains the untouched target cell 
population, with no bead-coupled antibodies on its surface. In case of the positive sort, the 
target population is retained in the magnetic field. To elute these cells after the positive sort, 
the MACS column was removed from the magnetic field and transferred onto a 15 mL tube. 
5 mL MACS buffer were added onto the column and a sterile stamp was used to push the 
labeled cells out of the MACS column. Positively sorted target cells were still labeled with the 
magnetic beads on its surface. Those beads are usually released after several days in culture. 
To evaluate the purity of the target cell population and the sort efficiency, 100 µL of cells 
suspension were taken from the eluate and transferred to an Eppendorf tube containing 
1 mL of MACS buffer (“post MACS sample”). The “pre MACS samples” and “post MACS 
samples” were analyzed with flow cytometric analyses (2.2.4) to evaluate the sort efficiency. 
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2.2.4) Analysis and separation of cells with FACS 
FACS is a flow cytometric method to analyze cell morphologies as well as the expression of 
surface molecules or intracellular molecules of cells, which allows not only the 
characterization of cell populations but also the ultrapure separation of cell populations 
according to their specific characteristics (Hulett et al., 1973). Morphological characteristics 
are assessed via the interpretation of the light scattering mediated by the cell structures. 
The forward scatter (FSC) reflects the relative cell size (a higher FSC correlates with a larger 
cell size) and the sideward scatter (SSC) mirrors the relative granularity of a cell (a high SSC 
correlates with a high granularity). In addition to scattering properties, cells can be 
fluorescently labeled using specific fluorophore-labeled antibodies. In the experiments 
described in this thesis, a FACS Canto II was used for the flow cytometric analysis of cells. A 
FACS Aria II was used for the analysis of distinct cell populations followed by the separation 
of cells. 
To stain the surface (2.2.4.1) or intracellular molecules (2.2.4.2) of cell populations, the 
following staining procedures were used. The subsequent analysis of FACS data was 
performed using the FlowJo analysis software. 
2.2.4.1) Surface staining 
To stain the surface of cell populations, cell suspensions were centrifuged (550 g, 5 min, 
4 °C), supernatants were removed and the cell pellets were washed twice with 1 mL of FACS 
buffer. After these washing steps the cell pellets were taken up in a staining solution, 
prepared with fluorescently labeled antibodies directed to the target antigens diluted in 
FACS buffer. If not otherwise mentioned, 100 µL of staining solution was used for up to 
10x106 cells. Cells were incubated with the staining solution for 10 min at 4 °C in the dark. 
After incubation, 1 mL of FACS buffer was added to the cell suspension to wash the cells. Cell 
suspensions were centrifuged (550 g, 5 min, 4 °C) and cell pellets were taken up in 
200-1000 µL FACS buffer, depending on cell number. The cell suspensions were then 
transferred in FACS tubes. If propidium iodide (PI) was used to stain dead cells, it was added 
at a concentration of 1:1000 into the cell suspension directly before acquisition at the flow 
cytometer. If fixable live/dead staining was used to stain dead cells, washing steps and 
preparation of staining solutions were performed with PBS instead of FACS buffer to avoid 
unspecific bindings. 
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The surface stained cell suspension could be either directly analyzed in the flow cytometer 
or used for further intracellular staining. 
2.2.4.2) Intracellular staining 
For intracellular staining, cells had to be fixed and permeabilized. Therefore cell suspensions 
were centrifuged (550 g, 5 min, 4 °C) and washed with PBS. For fixation, cells were incubated 
in 1 mL of 2 % PFA buffer (500 µL PBS + 500 µL 4 % PFA buffer) for 20 min at 4 °C in the dark. 
After fixation, all subsequent centrifugation steps were performed at 1000 g for 5 minutes at 
4 °C. Following fixation, cells were washed with PBS. For membrane permeabilization, 2 mL 
Saponine buffer were added to the cells and cell suspensions were centrifuged. The cell 
pellets were then washed with another 2 mL Saponine buffer to complete permeabilization. 
Cells were centrifuged and the supernatants were removed. For Fc-blocking, 70 µL Fc-
blocking solution (αCD16/αCD32, 1:70 in Saponine buffer) was added and incubated for 10 
min at 4 °C in the dark. For the intracellular staining 20 µL of staining solution, prepared with 
fluorescently labeled antibodies directed to the intracellular target antigens diluted in 
Saponine buffer were added. The dilution of the target antibodies were calculated for 100 µL 
of total staining volume (70 µL + 20 µL + cell pellet and Saponine residues). Incubation 
occurred for 20 min at 4 °C in the dark. After the intracellular staining, cells were washed 
with 2 mL Saponine buffer and in a second washing step with 2 mL FACS buffer. The washed 
cells were then resuspended in 200-300 µL FACS buffer, depending on the cell number. The 
cell suspensions were transferred to FACS tubes and acquired at the flow cytometer. 
2.2.5) Mouse dissections 
Prior to dissection of the target organs, surgery instruments were wiped with ethanol (70 %). 
Mice were either sacrificed via cervical dislocation or lethally anesthetized by the application 
of 1 mL/mouse anesthesia solution, containing Ketamine and Rompun in sterile NaCl 
solution (0.9 %). As soon as no reflexes were detectable, the surgery was started. The 
abdominal skin was opened and detached from the abdominal cavity. 
2.2.5.1) Spleen preparation 
To dissect the spleen, the abdominal cavity was opened with sterile scissors. Sterile pincettes 
were used to take out the spleen and to remove the attached pancreas. 
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2.2.5.2) Lymph node preparation 
For all lymph node experiments carried out in this thesis, the inguinal, axial and brachial 
lymph nodes were dissected and pooled. To dissect these lymph nodes, sterile pincettes 
were used. 
2.2.5.3) CNS preparation 
Prior to CNS dissection, mice were perfused with PBS to remove the whole blood from the 
mouse in order to avoid the presence of blood cells in the dissected CNS. Therefore the 
thorax of the mice was opened. The diaphragm was removed to enable access to the heart. 
A small incision was made into the right atrium. A syringe of PBS was used to inject 20-30 mL 
PBS into the left ventricle. After perfusion, the CNS and spinal cord were removed and 
transferred into a 15 mL tube containing 5 mL of IMDM. 
2.2.6) T cell culture 
For Th17 and Th2 cultures, naïve T cells (2.2.6.2) were co-cultured with antigen presenting 
cells (APC, 2.2.6.1) in the presence of αCD3e and polarizing cytokines (2.2.6.3) as described 
below. 
2.2.6.1) Isolation of APC 
For the isolation of APC, spleens (2.2.5.1) from cervically dislocated C57BL/6 mice (6 to 12 
weeks old) were dissected and transferred into a 15 mL tube containing 5 mL Wash medium 
(WM). Cells were put through a nylon mesh (100 µm) and resuspended in 50 mL WM. After 
centrifugation (550 g, 5 min, 4 °C), erythrocytes were lysed by resuspending the cell pellet in 
10 mL Lysis buffer. To stop the lysis, 5 mL WM were added. The cells were centrifuged again 
(550 g, 5 min, 4 °C) and taken up in 50 mL MACS buffer. Cells were counted manually 
(2.2.2.1) to determine the most appropriate reagent volume for the magnetic bead-based 
cell sort of CD90.2 negative cells. MACS was performed as described in 2.2.3. Thereby, the 
cell pellet was resuspended in 95 µL of MACS buffer and 5 µL of CD90.2 beads for every 
1x107 cells. The incubation occurred for 15 min at 4 °C. CD90.2-directed microbeads were 
used to label splenic lymphocytes without the capacity of antigen presentation. Throughout 
the magnetic cell sort, all CD90.2 positive cells were removed from the APC fraction, due to 
fixation in the magnetic field. The flow-through containing the unlabeled APC was 
centrifuged and the APC were taken up in 10 mL of sterile filtered mouse medium (MM). In 
order to avoid proliferation of APC in the co-culture with T cells and to limit APC lifetime 
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during culturing, APC were irradiated in a gamma irradiator, applying 3000 rad. Cells were 
then centrifuged (550 g, 5 min, 4 °C), taken up in 20-50 mL depending on the pellet size and 
counted manually (2.2.2.1). 
2.2.6.2) Isolation of naïve CD4+ T cells 
For the isolation of naïve CD4+ T cells, spleens (2.2.5.1) and lymph nodes (2.2.5.2) from 
cervically dislocated B6.2D2 mice, B6.2D2.CFP mice or B6.2D2.RFP mice (6 to 9 weeks old) 
were dissected and transferred into a 15 mL Tube, containing 5 mL WM. Cells were put 
through a nylon mesh (100 µm) and resuspended in 50 mL WM. After centrifugation (550 g, 
5 min, 4 °C), erythrocytes were lysed by resuspending the cell pellet in 10 mL Lysis buffer. To 
stop the lysis, 5 mL WM was added. The cells were centrifuged again (550 g, 5 min, 4 °C) and 
taken up in 20-50 mL MACS buffer, depending on the pellet size. Cells were counted 
manually (2.2.2.1) to determine the most appropriate reagent volume for the magnetic 
bead-based cells sort of naïve CD4+CD62Lhi cells. The magnetic bead-based sort of murine 
CD4+CD62Lhi T cells was performed using a Miltenyi CD4 isolation kit followed by a CD62L 
positive sort according to the manufacturer’s instructions and as described in 2.2.3. Thereby 
40 µL MACS buffer and 10 µL of the CD4 T cell biotin antibody cocktail were applied for every 
107 cells. The pellet was resuspended in the corresponding volume and incubated for 10 min 
at 4 °C in the dark. According to manufacturer`s instructions, 30 µL MACS buffer and 20 µL 
anti-biotin microbeads were added after this incubation. An additional incubation time of 
5 min followed. At this step 5 µL CD8 microbeads were added in addition to the anti-biotin 
microbeads to reduce the amount of contaminating CD8+ cells in the target fraction, which 
are hard to remove by purely applying the CD4 isolation kit. After this untouched sort of 
CD4+ cells, the efficiency was evaluated via flow cytometry (2.2.4). Therefore, αCD4-Horizon 
(1:400) and αCD3-APC (1:600) were used to stain these surface molecules. Usually, 
CD3+/CD4+ purity reached about > 90 % of the lymphocytes. The CD62L positive sort was 
performed subsequently. Therefore 960 µL of MACS buffer and 40 µL of CD62L microbeads 
were added to the cell pellet of enriched CD4-expressing cells. The incubation occurred for 
15 min at 4 °C in the dark. The efficiency of the cell sort was routinely analyzed via flow 
cytometry using αCD4-Horizon (1:400) and αCD62L-APC (1:200) antibodies. Only naïve T cells 
with purity better than 96 % were used for further experiments. Flow cytometry was also 
used to confirm the expression of Vβ11 of 2D2 cells with αVβ11-FITC (1:400).  
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2.2.6.3) T cell culture and differentiation 
To differentiate the naïve T cells (2.2.6.2) into Th17 cells or Th2 cells, cells were cultured on a 
24 well plate in 2 mL MM in the presence of 2 µg/mL αCD3e and with the irradiated CD90+-
depleted C57BL/6 splenic APC (2.2.6.1), at a one-to-ten ratio. The following cytokines were 
added for the initial stimulation into Th17 or Th2 differentiation. 
Th17 3 ng/mL TGF-β 
20 ng/mL IL-23 
20 ng/mL IL-6 
Th2 10 ng/mL IL-4 
10 µg/mL αIFN-γ 
10 µg/mL αIL-12 
After 3 and 5 days of culture, T cells were split and fed with the following cytokines. 
Th17 50 U/mL IL-2 (d3); 25 U/mL IL-2 (d5) 
10 ng/mL IL-23 (d3 and d5) 
Th2 100 U/mLIL-2 (d3) 
10 ng/mL IL-4 (d5) 
Th2 cells were used for co-cultures with hippocampal slices (2.2.15) after 5 days of culture. 
Th17 cells were either used for co-cultures after 5 days of culture or restimulated after one 
week. For the restimulation, Th17 were harvested, counted and seeded on 24-well plates 
with freshly isolated, irradiated CD90+-depleted C57BL/6 splenic APC (2.2.6.1), at a one-to-
five ratio and in the presence of 2 µg/mL αCD3e. The following cytokines where added for 
the restimulation. 
Th17 0.75 ng/mL TGFβ 
20 ng/mL IL-23 
10 ng/mL IL-6 
Restimulated cells were used three days after the restimulation for further experiments (co-
culture with organotypic hippocampal slices or induction of passive transfer EAE). 
2.2.6.4) Cytokine check in T cell cultures 
Cytokine expression was routinely checked on day 5 and day 10 of culture using flow 
cytometry to detect successful T cell polarization. 24 h prior to the cytokine check, one well 
per culture was coated on a 48-well plate with αCD3e and αCD28 antibodies. Therefore 
120 µL PBS, containing 3 µg/mL αCD3e and 2.5 µg/mL αCD28 were applied per well. The 48-
well plate was covered with a cling film pre-sprinkled with 70 % EtOH and incubated at 4 °C 
BEATRICE WASSER  MATERIALS AND METHODS 
37 
 
overnight. For stimulation, the coating solution was removed. 2 mL of the T cell culture were 
resuspended and divided into each 1 mL cell suspension, which was transferred to either the 
coated or to an uncoated control well of the 48-well plate. Brefeldin A was added with a final 
concentration of 5 µg/mL into each well to block the cytokine secretion of the cells. After 4h 
of stimulation, cells were harvested for the FACS staining which was performed according to 
(2.2.4) using CD4-PECy7 (1:1000) for extracellular staining, Fc-blocking solution (1:100) and 
IFN-γ-Horizon (1:200), IL-17-APC (1:200) and TNFa-AF700 (1:200) for intracellular staining 
analyzing Th17 cells. If Th2 cells were analyzed, an additional intracellular staining of IL-10-
APC (1:200) was performed. Th17 cells usually yielded 30-40 % IL-17 and no IFN-γ 
expression, while Th2 cells lacked the expression of both IFN-γ and IL-17 but showed low IL-
10 expression. 
2.2.7) EAE 
All animal experiments were conducted according to the German Animal Protection Law. For 
active C57BL/6 EAE, mice were immunized subcutaneously with 200 µL of a myelin 
oligodendrocyte protein (MOG)35–55 emulsion in complete Freund adjuvant (CFA) (Hooke kit). 
Additionally, C57BL/6 mice received 200 ng pertussis toxin (PTX) intraperitoneally (i.p.) at 
the time of immunization and after 24 h. For active SJL/J EAE, mice were immunized 
subcutaneously (s.c.) with 200 µL a proteolipid protein (PLP)139-151 emulsion in 200 µL CFA 
(Hooke kit). SJL/J mice received 500 ng PTX i.p. at the time of immunization. 
For adoptive transfer EAE, 10-30x106 2D2.RFP Th17 cells (2.2.6) were injected intravenously 
(i.v.) into B6.CX3CR1.GFP mice and PTX (400 ng/mouse) was injected on the day of transfer 
as well as on day 2 following transfer. 
Mice were checked for clinical symptoms daily, and signs of EAE were translated into a 
clinical score as follows. Classical disease: 0, no detectable signs of EAE; 0.5, tail weakness; 1, 
complete tail paralysis; 2, partial hind limb paralysis; 2.5, unilateral complete hind limb 
paralysis; 3, complete bilateral hind limb paralysis; 3.5, complete hind limb paralysis and 
partial forelimb paralysis; 4, total paralysis of forelimbs and hind limbs; 5, moribund or day 
after death. Atypical disease: 0, no detectable signs of EAE; 1: tail paralysis, hunched 
appearance, unsteady walk; 2: ataxia, head tilt 3: severe ataxia, spasticity or knuckling; 4 
moribund. 
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2.2.8) Isolation of CD11c+ myeloid cells for RNA-Sequencing 
CD11c+ myeloid cells were purified out of freshly isolated mononuclear cells from the CNS 
(2.2.8.1) and from splenocytes (2.2.8.2) of EAE-diseased mice. In order to enrich CD11c+ 
cells, a positive MACS was performed (2.2.8.3). Highly pure CD11c+ cells were finally 
obtained using FACS (2.2.8.4). These cells were taken up in 350 µL RLT buffer (implemented 
in RNA isolation kits) and resuspended carefully by up and down pipetting (at least ten 
times) using a syringe (20 G) in order to allow complete lysis of the cells. Lysed cells were 
stored at -80 °C until RNA isolation (2.2.9.1). 
2.2.8.1) Isolation of myeloid cells from the CNS 
Dissected CNS tissue was transferred into a 15 mL tube containing 5 mL IMDM (2.2.5.3). Up 
to three CNS samples were pooled in one tube. To cut the CNS into small pieces, samples 
were transferred into cell culture dishes and fragmented with a scalpel. CNS fragments and 
IMDM were then retransferred into the 15 mL tube. To allow the isolation of single CNS-
derived cells, CNS samples were treated with 10 mg/mL Collagenase/Dispase, 10 mg/mL 
Collagenase and 200 U/mL DNase to remove intrinsic collagen fibers, DNA and fibronectin. 
Digestion was performed for 30 min at 37 °C in a water bath, while the samples were swirled 
every 5 min. After digestion, the CNS tissue was put through a nylon mesh (70-100 µm), 
washed with 45 mL IMDM and centrifuged (550 g, 5 min, 4 °C). CNS mononuclear cells were 
separated by a 30/70 Percoll gradient. Therefore, CNS cell pellets were resuspended in 5 mL 
30 % Percoll (in IMDM) per CNS. 5 mL of 70 % Percoll (in PBS) was then carefully overlayed 
with each 5 mL of the cell suspension. Density centrifugation was performed at 750 g for 30 
min with an acceleration- and deceleration-unit of 1 each. Light and fatty compartments on 
top of the 30 % Percoll were removed with a 1 mL pipet and discarded. To collect 
mononuclear cells, the cell layer at the interface between the 30 % Percoll layer and the 
70 % Percoll layer was collected and transferred to a 50 mL tube containing 40 mL MM. At 
this step, samples from up to seven mice were pooled. Cells were centrifuged (550 g, 5 min, 
4 °C) and taken up in 1 mL MM for automatic cell counting using the Bio-Rad cell counter 
(2.2.2.2). 
2.2.8.2) Isolation of splenic myeloid cells 
Dissected spleens were transferred into a 15 mL tube containing 5 mL WM (2.2.5.1). Up to 
three spleens were pooled in one tube. To cut the spleens into small pieces, spleens and 
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WM were transferred into cell culture dishes and fragmented with a scalpel. Spleen 
fragments and WM were retransferred to the 15 mL tube. To allow the isolation of single 
spleen cells, splenic collagen was digested via treatment with 10 mg/mL Collagenase for 30 
min at 37 °C, while the samples were swirled every 5 min. After digestion, spleen tissue was 
put through a nylon mesh (70-100 µm), washed with 45 mL WM and centrifuged (550 g, 5 
min, 4 °C). Erythrocytes were lysed by resuspending the cell pellet in 10 mL lysis buffer. 
Following resuspension, the lysis was stopped by the addition of 5 mL WM. Spleen cells were 
then centrifuged (550 g, 5 min, 4 °C) and the cell pellet was taken up in 50 mL WM. Cells 
were automatically counted using a Bio-Rad cell counter (2.2.2.2). 
2.2.8.3) MACS CD11c+-cell enrichment 
For CD11c+-cell enrichment, single cells from the CNS (2.2.8.1) and the spleen (2.2.8.2) were 
labeled with αCD11c microbeads to perform bead-based MACS according to manufacturer’s 
instructions (2.2.3). For all experiments, the total amount of the CNS-derived mononuclear 
cells obtained were used for the MACS enrichment, while a maximum of 1x108 splenocytes 
were enriched for one experiment. According to the cell count, 100 µL of αCD11c beads and 
400 µL MACS buffer per 108 cells were used for the sort. The incubation time was 15 min. In 
order to optimize the sort efficiency, αCD16/CD32-antibodies (1:100) were added before the 
incubation with the αCD11c microbeads. 
2.2.8.4) FACS of CD11c+ cells 
After the CD11c positive MACS enrichment (2.2.8.3), cell suspensions were centrifuged 
(550 g, 5 min, 4 °C) to proceed with a FACS surface staining (2.2.4.1). During FACS surface 
staining, the cell pellets were each stained with 1 mL of an antibody cocktail containing 
fluorescently labeled antibodies against CD11c, CD45, CD45.1, CD90.2, I-A[b] and I-A[K], 
depending on the target cell population. Staining was performed in 15 mL tubes, which were 
filled with MACS buffer for the washing steps. Subsequently, target cell populations 
(CD45+CD90-CD11c+ myeloid cells or CD45+CD90-CD11c+MHCII+ myeloid cells) were sorted 
using the FACS Aria II. 1 mL of MM was prefilled in the collection tube to host the sorted 
cells. The purity of the sorted populations ranged from 90 to 99 % of living cells. Finally, the 
cell suspensions were centrifuged to remove the supernatant. The sorted cells were stored 
in 250 µL RLT buffer at -80 °C. 
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2.2.9) RNA Isolation 
RNA from less than 5 x 105 cells was isolated using RNeasy® Micro Kit (2.2.9.1); RNA from 
more than 5 x 105 cells was isolated using RNeasy® Mini Kit (2.2.9.2). The first resuspension 
steps were performed by up and down pipetting (at least ten times) in RLT buffer using a 
syringe (20 G) in order to allow complete lysis of the cells. 
2.2.9.1) RNA isolation using RNeasy® Micro Kit 
The RNA isolation was performed according to the manufacturer’s instructions. 
Consequently, cells were resuspended and homogenized in 350 µL RLT buffer. 350 µL of 
70 % ethanol (freshly prepared from 100 % ethanol and RNAse-free water) were added to 
the lysate and the sample was mixed by pipetting. The sample was then transferred to an 
RNeasy MinElute spin column in a 2 mL collection tube and centrifuged (8000 g, 15-60 s, at 
room temperature (RT)). The flow-through was discarded before the column was washed 
with 350 μL RW1 buffer. The sample was centrifuged (8000 g, 15-60 s, RT) and the flow-
through was again discarded. 10 μL DNase I stock solution was diluted in 70 μL RDD buffer to 
freshly prepare 80 µL of a DNase I incubation mix, which was transferred to the column 
membrane. Incubation occurred at RT for 15 min to allow DNA digestion. 350 μL RW1 buffer 
were then used to wash to the column. After centrifugation (8000 g, 15-60 s, RT), the 
collection tube was discarded. The column was placed in a new 2 mL collection tube and 
washed with 500 μL RPE buffer. After centrifugation (8000 g, 15-60 s, RT), the flow-through 
was discarded. An additional washing step was performed with 500 μL of 80 % ethanol 
(freshly prepared from 100 % ethanol and RNAse-free water) (8000 g, 15-60 s, RT). The 
column was again placed in a new 2 mL collection tube. To dry the membrane, the lid of the 
column was opened before the next centrifugation step (21000 g, 5 min, RT). To elute the 
RNA, the column was placed in a 1.5 mL collection tube, 20 μL RNase-free water were added 
directly to the center of the column membrane and the column was centrifuged (21000 g, 
1 min, RT). The RNA was either directly used for further experiments or stored at -80 °C. 
2.2.9.2) RNA isolation using RNeasy® Mini Kit 
The RNA isolation was performed according to the manufacturer’s instructions. 
Consequently, cells were resuspended and homogenized in 350 µL RLT buffer. 350 µL of 
70 % ethanol (freshly prepared from 100 % ethanol and RNAse-free water) were added to 
the lysate and the sample was mixed by pipetting. The sample was transferred to an RNeasy 
BEATRICE WASSER  MATERIALS AND METHODS 
41 
 
Mini spin column placed in a 2 mL collection tube and centrifuged (8000 g, 15-60 s, RT). The 
flow-through was discarded before the column was washed with 500 μL RPE buffer. The 
sample was centrifuged (8000 g, 15-60 s, RT) and the flow-through again discarded. This 
washing step was repeated using 500 RPE buffer (8000 g, 2 min, RT). The column was placed 
in a new 2 mL collection tube and centrifuged to dry the membrane (21000 g, 1 min, RT). To 
elute the RNA, the column was placed in a 1.5 mL collection tube, 87 μL RNase-free water 
were added directly to the center of the column membrane and the column was centrifuged 
(21000 g, 1 min, RT). For DNA digestion, the sample was treated with 10 µL 10x incubation 
buffer and 2 µL DNAse from the Roche DNase kit. 1 µL RNAseOUT from the Superscript III 
First Strand Synthesis System was additionally applied in order to prevent RNA degradation. 
This mixture was incubated for 20 min at 37 °C. The reaction was stopped using 2 µL 0.2 M 
EDTA. 350 µL RLT buffer (containing 10 µL β-mercaptoethanol per 1 mL) were added and 
mixed well with the sample. Additionally, 250 µL ethanol (96-100 %) was added. Divergent 
from the manufacturer’s instructions, the well-mixed sample (700 μL) was then transferred 
to an RNeasy MinElute spin column instead of an RNeasy Mini spin column. After 
centrifugation (21000 g, 30 s, RT), the column was transferred to a new 2 mL collection tube. 
The sample was washed with 500 µL RPE buffer and centrifuged (21000 g, 30 s, RT). An 
additional washing step was performed using 500 µL ethanol (80 %). After centrifugation 
(21000 g, 2 min, RT), the column was again transferred to a new 2 mL collection tube, 
opened and centrifuged again to dry the membrane (21000 g, 5 min, RT). To elute the RNA, 
the column was placed in a 1.5 mL collection tube, 20 μL RNase-free water were added 
directly to the center of the column membrane and the column was centrifuged (21000 g, 
1 min, RT). The RNA was either directly used for further experiments or stored at -80 °C. 
2.2.10)  RNA quantification and quality assessment 
RNA samples destined for qRT-PCR analyses were quantified using the NanoDrop. For this, 
1 µL of the diluted RNA samples was applied on the spectrophotometer and the NanoDrop 
software was used to determine RNA quantity.  
RNA samples planned for RNA sequencing (RNA-Seq) analyses were quantified using a 
Qubit® 2.0 fluorometer and the Qubit RNA assay kit. According to the manufacturer’s 
instructions, the Qubit™ working solution was prepared by diluting the Qubit™ RNA reagent 
1:200 in Qubit™ RNA buffer in a 1.5 mL Eppendorf tube. 199 µL Qubit™ working solution 
were transferred into a thin-wall, clear 0.5 mL optical-grade real-time PCR tube (Qubit™ 
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Assay Tube) and 1 μL of the RNA sample were added. The sample was mixed well by 
vortexing 2–3 seconds, before it was incubated at room temperature for 2 minutes. The 
sample tube was then inserted into the Qubit® 2.0 fluorometer and the detection process 
was started. Dependent on the RNA concentration, a part of the RNA sample was diluted in 
RNAse-free water to avoid a final concentration above 3 ng/µL during quality assessment. 
To assess RNA quality, the Bioanalyzer 2100 was used with the Agilent RNA 6000 pico kit 
according to the manufacturer’s instructions. Consequently, the required gel-dye mix was 
prepared by adding 1 μL of RNA 6000 Pico dye concentrate to a 65 μL aliquot of filtered gel. 
The sample was then vortexed thoroughly and centrifuged (13000 g, 10 min, RT). The gel-
dye mix was equilibrated to RT for 30 minutes in the dark before use. The chip was placed on 
the chip priming station and 9.0 μL of the gel-dye mix were pipetted at the bottom of the 
marked well and dispensed. The chip priming station was closed and the plunger of the 
syringe was pressed from the 1 mL position down until it was held by the clip. After 30 s the 
plunger was released and pulled back to the 1 mL position after additional 5 s. The chip 
priming station was then opened and 9.0 μL of the gel-dye mix was pipetted in each of the 
accordingly marked wells. Then 9 μL of the RNA 6000 Pico conditioning solution were 
pipetted into the respective marked well. Further, 5 μL of the RNA 6000 Pico marker were 
pipette into the respective wells. 1 μL of the diluted RNA 6000 Pico ladder were pipetted 
into the accordingly marked well. Lastly, 1 μL of each sample were transferred into the 
sample wells. The chip was placed horizontally in the adapter of the IKA vortex mixer and 
vortexed for 60 s at 2400 rpm. After vortexing, the chip was transferred into the Bioanalyzer 
and RNA quality was assessed using the 2100 expert software. Only samples with an RNA 
integrity number (RIN) >7.4 were used for the library preparation for RNA-Seq. 
2.2.11)  mRNA Sequencing (mRNA-Seq) 
Deep mRNA sequencing (mRNA-Seq) is a fulminant tool, allowing the analysis of the whole 
cell transcriptome, with a highly precise detection of transcript levels and their isoforms 
superior to other methods (Wang et al., 2009). Taking advantage of mRNA-Seq allows the 
identification of changes in gene expression patterns in cells (Wang et al., 2009) and thus 
enables the identification of gene expression patterns controlling myeloid cell function and 
potentially influencing disease states, such as exacerbation and remission of EAE or MS. For 
mRNA-Seq, RNA samples with an RIN >7.4 were used. The cDNA was synthesized from RNA 
as described by Picelli et al. (Picelli et al., 2014)(2.2.11.1). After the determination of the 
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cDNA quantity (2.2.11.2), 1 ng of the cDNA was used for the library preparation (2.2.11.3). 
The library size distribution was assessed (2.2.11.4) before sequencing was performed using 
the MiSeq (2.2.11.5). 
2.2.11.1) cDNA synthesis 
According to Picelli et al. (Picelli et al., 2014), the respective amount of RNA was pipetted 
into a 0.2 mL PCR tube containing 1 µL RNAse-free water from the RNA isolation kits, 1 µL 
RNAseOUT from the Superscript III First Strand Synthesis System, 1 µL of oligo-dT primer 
(10 µM) and 1 µL of dNTP mix (10 mM). The respective amount of reagents required for all 
samples was calculated and a reaction mix was prepared, which was then distributed to the 
sample tubes to guarantee equal reaction conditions for every sample. After adding the 
RNA, the sample tubes were quickly vortexed, spun down and placed on ice. The samples 
were then incubated for 3 min at 72 °C to allow oligo-dT primer hybridization to the poly(A) 
tail of mRNA molecules. After this incubation, the samples were put on ice, spun down, and 
placed back on ice. For reverse transcription, the reverse transcription mix for all reactions 
was prepared by combining the reagents listed below. 
Component Volume [µL] Final concentration 
SuperScript II reverse transcriptase (200 U/µL) 0.5 100 U 
RNAse inhibitor (40 U/µL) 0.25 10 U 
Superscript II first-strand buffer (5x) 2 1x 
DTT (100 mM) 0.25 5 mM 
Betaine (5 M) 2 1 M 
MgCl2 (100 mM) 0.9 6 mM 
TSO (10 µM) 1 1 µM 
Nuclease-free water 0.1  
 
7 µL of this mix was then added to the samples. The samples were spun down and incubated 
in a thermal cycler as described below. 
 Cycle Temperature ( °C) Time 
1 42 90 min 
2-11 50 2 min 
 42 2 min 
12 70 15 min 
13 4 hold 
 
After this incubation 40 µL of the following PCR mix were added. 
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Component Volume [µL] Final 
concentration 
KAPA HiHi HotStart 
ReadyMix (2x) 
25 1x 
IS PCR primers (10 µM) 1 0.1 µM 
Nuclease-free water 14  
 
To amplify cDNA, PCR was performed using the following program. Dependent on the 
inserted RNA amount, the number of PCR amplification cycles was altered (usually, 16-17 
cycles). 
Cycle Temperature ( °C) Time 
1 98 3 min 
2-18 98 20 s 
 67 15 s 
 72 6 min 
19 72 5 min 
20 4 hold 
 
For cDNA purification, 50 µL of well-mixed Ampure XP beads were added to each sample and 
mixed by pipetting. Incubation occurred for 8 min at RT to allow DNA binding to the beads. 
The 96-well plate containing the samples was placed on a magnetic stand for 5 min. 
Subsequently, the liquid was carefully removed without disturbing the beads. The beads 
were then washed with 200 µL ethanol (80 %, freshly prepared). After 30 s incubation, the 
ethanol was removed and washing was repeated with fresh ethanol (80 %, freshly prepared). 
Following the second washing step, ethanol was completely removed and the beads were 
dried for 5 min. To elute the purified cDNA, the beads were resuspended in 17.5 µL EB 
solution and incubated for 2 min. The plate was again placed on the magnetic stand for 
2 min. 15 µL of the supernatant were collected. The cDNA was either directly used for DNA 
quantity- and quality-assessment or stored at -20 °C. 
 2.2.11.2) cDNA quantification  
DNA samples were quantified using a Qubit® 2.0 fluorometer and the Qubit dsDNA HS assay 
kit. According to the manufacturer’s instructions, the Qubit™ working solution was prepared 
by diluting the Qubit® dsDNA HS reagent 1:200 in Qubit® dsDNA HS buffer in a 1.5 mL 
Eppendorf tube. 199 µL Qubit™ working solution were transferred into a thin-wall, clear 
0.5 mL optical-grade real-time PCR tube (Qubit™ Assay Tubes) and 1 μL of the cDNA sample 
were added. The sample was mixed well by vortexing 2–3 seconds, before it was incubated 
at room temperature for 2 minutes. The sample tube was then inserted into the Qubit® 2.0 
fluorometer and the detection process was started. Dependent on the DNA concentration, a 
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part of the cDNA sample was diluted in nuclease-free water from the RNA isolation kits to 
obtain a final concentration of 0.2 ng/µL. 
2.2.11.3) Library preparation 
The Nextera xt DNA library preparation kit was used to prepare the cDNA library. According 
to the manufacturer’s instructions 10 µL of TD buffer was pipetted into each sample well of a 
96-well plate. 5 µL of the cNDA (0.2 ng/mL) was subsequently added. After additionally 
adding 5 µL ATM to each well, samples were mixed by pipetting up and down five times. The 
sample plate was centrifuged (280 g, 1 min, RT) and transferred into a thermal cycler to 
incubate at 55 °C for 5 min and to then cool down to 10 °C. Once the sample reached 10 °C, 
5 µL NT buffer was added to each sample well, mixed with the sample by pipetting, 
centrifuged (280 g, 1 min, RT) and incubated for 5 min at RT. Subsequently, 15 µL of NPM 
was added to each well. In every sequencing run, four different samples were compared. To 
distinguish between samples, different index primers (e.g. n701 and s501, n702 and s502, 
n703 and s503 or n704 and s504) were applied to each sample and mixed well with the 
sample by pipetting. The samples were centrifuged (280 g, 1 min, RT) before the following 
thermal cycle was performed in a thermal cycler. 
 
Cycle Temperature ( °C) Time 
1 72 3 min 
2 95 30 s 
3-14 95 10 s 
 55 30 s 
 72 30 s 
15 72 5 min 
16 10 hold 
 
In order to purify the cDNA libraries, the samples were centrifuged (280 g, 1 min, RT) and 
transferred into a new 96-well plate. 90 µL of AMPure XP beads were added to each sample 
well and mixed with the samples by pipetting. Subsequent incubation occurred for 5 min at 
RT, before the plate was placed on a magnetic stand for 2 min. The supernatant was then 
discarded and replaced by 200 µL ethanol (80 %, freshly prepared) to wash the beads. After 
30 s of incubation, the ethanol was replaced by 200 µL fresh ethanol (80 %, freshly prepared) 
for a second washing step. The ethanol was again removed after 30 s and the beads were 
air-dried for 15 min. 52.5 µL RSB were then added, mixed well with the sample and 
incubated for 2 min. The plate was then placed on the magnetic stand for 2 min. 50 µL of the 
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clear supernatant containing the purified cDNA libraries were finally transferred into a new 
96-well plate. The cDNA was quantified according to (2.2.11.2), before the cDNA library size 
distribution was assessed (2.2.11.4). 
2.2.11.4)  cDNA library size distribution assessment 
To assess cDNA library size distribution, the Bioanalyzer 2100 was used with a high 
sensitivity DNA kit according to the manufacturer’s instructions. Consequently, the required 
gel-dye mix was prepared by pipetting 15 μL of the dye concentrate into a high sensitivity 
DNA gel matrix vial. The tube was vortexed for 10 s and transferred to a spin filter, which 
was then centrifuged (2240 g, 10 min, RT). The gel-dye mix was equilibrated to RT for 30 
minutes in the dark before use. The chip was placed on the chip priming station and 9.0 μL 
of the gel-dye mix were pipetted at the bottom of the marked well and dispensed. The chip 
priming station was closed and the plunger of the syringe was pressed from the 1 mL 
position down until it was held by the clip. After 30 s, the plunger was released and pulled 
back to the 1 mL position after additional 5 s. The chip priming station was then opened and 
9.0 μL of the gel-dye mix was pipetted in each of the accordingly marked wells. Then 5 μL of 
the high sensitivity DNA marker were pipetted into the respective marked well and into all 
sample wells. 1 μL of the high sensitivity DNA ladder was pipetted into the accordingly 
marked well. Finally, 1 μL of each sample was transferred into the sample wells and 1 µL of 
ladder to every unused sample well. The samples were diluted to a concentration of 2 ng/mL 
before use. The chip was then placed horizontally in the adapter of the IKA vortex mixer and 
vortexed for 60 s at 2400 rpm. After vortexing, the chip was transferred into the Bioanalyzer 
and cDNA quality and library size distribution was assessed using the 2100 expert software. 
To proof the adequate quality of the cDNA used for the library preparation, cDNA samples 
were assessed in parallel. 
The cDNA library molarity was calculated based on the determined average size according to 
the following formula: c = c(library) x 1000 x 1/649 x 1/(Average Size) x 1000 nM. 
2.2.11.5) Sequencing with Miseq 
Sequencing was performed on a MiSeq with MiSeq Reagent Kit v3. Accordingly, 5 µL from 
each of the target cDNA libraries (pre-diluted to 4 nM) were pooled in a 1.5 mL Eppendorf 
tube. 5 µL of the pooled library were transferred to a new 1.5 mL Eppendorf tube and 5 µL of 
NaOH (0.2 N) was added. Incubation occurred for 5 min to allow denaturation before it was 
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stopped by adding 990 µL HT-1 buffer to obtain a 20 pM library. 540 µL of the library were 
diluted with 60 µL HT-1 buffer to obtain 600 µL of a 18 pM library, which was finally 
transferred in a MiSeq chamber into the MiSeq. Sequencing was started and sequencing 
data were analyzed with CLC Genomic Workbench 7.0. 
2.2.12) RNA-Seq statistics 
Alignment of RNA-Seq data to the mouse genome (Mm9) and quantification of aligned reads 
per gene (counts) was conducted using CLC Genomics Workbench software 7.0. All statistical 
analyses of RNA-Seq data were performed in R (v3.2.0) using Bioconductor routines (Huber 
et al., 2015) in collaboration with the Institute of Medical Biostatistics Epidemiology and 
Informatics of the Johannes Gutenberg University Medical Center in Mainz, Germany. After 
alignment, genes with less than 10 aligned reads in at least one sequencing library were 
discarded. Significant differences in aligned reads per gene between the different disease 
conditions and the distinct organs were assessed using the Bioconductor (R) packages DESeq 
(Anders and Huber, 2010) (v1.2) and EdgeR (Robinson et al., 2009) (v3.10). Differences 
between the disease conditions were analyzed separately in each mouse model. 
Normalization for sequencing depth was performed using the normalization procedure 
implemented in DESeq. Generalized linear models and likelihood ratio tests implemented in 
EdgeR (McCarthy et al., 2012) were employed to detect genes with significantly different 
expression between the analyzed conditions. P-values were adjusted for multiple testing 
using the Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995). Genes with 
adjusted p-values < 0.05 which is equivalent to a false discovery rate (FDR) of 5 % were 
flagged as significant in the subsequent analysis. Principal component analysis (PCA) was 
performed on variance-stabilized expression data. After normalization for sequencing depth, 
counts per gene were transformed using a variance-stabilizing transformation implemented 
in DESeq. The 100 most variable genes were used for the PCA. Clustering of samples based 
on their scores on the two principal components that accounted for the highest amount of 
expression variability was visually inspected. 
2.2.13) qRT-PCR 
For qRT-PCR, RNA was transcribed into cDNA using the SuperScript® III First Strand Synthesis 
System following the manufacturer’s instructions. Per reaction, 1 µg RNA was used in a 
reaction volume of 50 µL. If less material was available all RNA was used. 5 µL of random 
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hexamer primers (50 ng/µL) were added to 18 µL of the diluted RNA sample. To allow primer 
hybridization, samples were incubated for 5 min at 65 °C. The tubes were then placed on ice 
and 27 µL of the following reaction mix was added to each sample: 
Component Volume [µL] 
MgCl2 10 
10x RT buffer 5 
0.1 M DTT 5 
dNTP mix (10 mM each) 5 
RNaseOUT 1 
Superscript III reverse transcriptase 1 
 
The samples were then transferred into a thermal cycler and the following program was 
started: 
Cycle Temperature ( °C) Time 
1 25 10 min 
2 50 50 min 
3 85 5 min 
4 4 hold 
 
If 1 µg RNA was used for cDNA syntheses, the resulting cDNA was diluted with 150 µL 
nuclease-free water. If less RNA was applied, the cDNA was utilized without dilution for qRT-
PCR. 
For qRT-PCR, 4 μL of cDNA was amplified using iQ SYBR® Green supermix in a CFX Connect™ 
Real Time Detection System. Therefore, 100-400 nM of the respective forward and reverse 
primers (2.1.9; designed using Beacon Designer 8 Software and subsequently tested for 
amplification efficiency and specificity) were added to 10 µL of the iQ SYBR® Green 
supermix. Nuclease-free water was used to fill each reaction mix up to 16 µL. The reaction 
mix was then pipetted into 4 µL of the diluted RNA sample on a clear 96-well plate. The plate 
was placed in the CFX Connect™ Real Time Detection System and the following thermal cycle 
was performed: 
Cycle Temperature ( °C) Time Comment 
1 95 3 min  
2-41 95 10 s  
 Tm* 45 s * Tm varied depending on 
the target gene (2.1.9)   Plate read 
42 95 1 min  
43 55 1 min  
44 55-95 Increment: 0.5 °C /10s Melt curve 
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Technical triplicates of gene expressions were applied to ensure accuracy of the quantity 
determination. Data were analyzed using Bio-Rad CFX Manager Software. Only triplicates 
with an SD < 0.5 were used for the analysis. As described above, amplification was 
performed for 40 cycles. Samples which were not detectable were included in the analysis 
with a Cq value of 40. Gene expression was normalized to β-actin expression as described in 
(Vogelaar et al., 2009). 
2.2.14) Generation of bone marrow derived dendritic cells (BMDC) and bone marrow derived 
macrophages (BMDM) 
Bone marrow cells were isolated from the tibias and femurs of C57BL/6 mice. Therefore, the 
tibias and femurs were flushed with PBS into a petri dish filled with WM. The cells were 
resuspended in WM and filtered through a nylon mesh (100 µm) to remove remaining bone 
fragments and fat leftovers. The filtered cells were filled up with WM to 30 mL and 
centrifuged (550 g, 5 min, 4 °C). The pellet was resuspended and the cell count was 
determined by manual cell counting (2.2.2.1). 
For the in vitro generation of BMDC, cells were incubated in 100 mm2 cell culture dishes at a 
concentration of 5 x 106 cells/cell culture dish. Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) was added to the culture medium (MM). After 4 days, half of the culture 
medium was carefully removed and replaced with fresh culture medium containing GM-CSF. 
For classical activation, LPS was added at a final concentration of 10 µg/mL to the culture. 
For alternative activation, LPS (final concentration of 10 µg/mL), IL-4 (final concentration of 
10 ng/mL) and dexamethasone (final concentration of 5 × 10−7 M) were added to the culture. 
In such a way the cells were stimulated for 3 days. 
For the in vitro generation of BMDM, cells were incubated in 75 cm2 cell culture flasks. 
Macrophage colony-stimulating factor (M-CSF) was added to the culture medium at a 
concentration of 20 ng/mL. After 4 days, the culture medium was replaced with fresh culture 
medium containing M-CSF. For classical activation, LPS was added at a final concentration of 
10 µg/mL to the culture. For alternative activation, LPS (final concentration of 10 µg/mL), IL-
4 (final concentration of 10 ng/mL) and dexamethasone (final concentration of 5 × 10−7 M) 
were added to the culture. In such a way the cells were stimulated for 3 days. 
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2.2.15) Organotypic hippocampal slice (co-)culture 
For organotypic hippocampal slice cultures, P2–P6 pups of B6.CX3CR1GFP/GFP mice were 
decapitated. The brain was rapidly removed and transferred to ice-cold slice preparation 
medium. Both hemispheres from the brain were separated and the meninges were 
removed. The hippocampi were isolated with adjacent cortical parts and coronally cut into 
300 μm-thick slices using a McILWAIN tissue chopper. Intact hippocampal slices were then 
transferred onto Millicell cell culture inserts and cultivated for 7 to 14 days in slice culture 
medium. The medium was changed 24 h after the isolation of the hippocampus and then 
every other day. After 7 to 14 days of culture, hippocampal slices were used for experiments. 
For co-cultures either 1 x 105 Th17 or 1 x 105 Th2 cells were added in a volume of 10 µL on 
top of the hippocampal slices and cultured for 24 h. To modify the interactions between the 
T cells and microglia in the slice tissue, the following reagents were added. 
Reagent Final 
concentration 
Application 
Annexin V 10 µg/mL Into T cell medium and slice culture medium on the day the 
co-culture was started (24 h before imaging) 
Wortmannin 2.5-5 µM Into T cell medium and slice culture medium on the day the 
co-culture was started (24 h before imaging) 
LPS 1 µg/mL For LPS pre-activation, organotypic slices were treated with 
LPS for 24 h prior to T cell addition (48 h before imaging). 
LPS was kept in the medium during the co-culture. 
GlcNAc 20-40 mM Into slice culture medium 24 h before the co-culture was 
started (48 h before imaging). Additional 20 mM GlcNAc 
was added to the slice culture medium 20-30 min before 
the co-culture was started and with the T cells on top of the 
slices, when the culture was started (24 h before imaging). 
 
  
2.2.16) Two-photon imaging 
2.2.16.1) In vivo experiments 
Two-photon experiments were performed with EAE-diseased B6.CX3CR1GFP/GFP;+/GFP.Rag-/-;-/+ 
mice. EAE was induced by the transfer of pathogenic fluorescently labeled T cells into the 
recipient mice (s. 2.2.7). Operation procedures and two-photon laser scanning microscopy 
(TPLSM) for in vivo imaging experiments were performed as described previously (Herz et al., 
2010; Luchtman et al., 2016; Siffrin et al., 2010a). Briefly, mice were anesthetized with 
isoflurane and then continuously respirated using 1.5 % isoflurane in oxygen/nitrous oxide 
(1:2) via a facemask. The anesthetized animal was transferred to a custom-built surgery and 
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microscopy table and fixed in a hanging position with the head inclined to allow access to 
regions deeper in the brainstem. The brainstem was exposed for imaging by carefully 
removing musculature above the dorsal neck area and carefully removing the dura mater. A 
sterile agarose patch (0.5 % in 0.9 % NaCl solution) was installed on the exposed brain 
surface which was used to capture a PBS bath that was continuously exchanged by a 
peristaltic pump. During surgery and imaging, body temperature was maintained at 
35-37 °C. The depth of anesthesia was controlled by continuous CO2 measurements of 
exhaled gas. Dual near-infrared and infrared excitation of the brainstem was applied at 
850 nm by an automatically tunable Ti:Sa laser and at 1110 nm by an optical parametric 
oscillator (OPO) pumped by the Ti:Sa laser. Volumes of approximately 300 µm x 300 µm x 
72 µm were acquired over time using an Olympus XLUMPlanFI 20x/0.95 W objective on a 
TriMScope I from LaVision Biotec and exported as TIFFs for 3D analyses. 
2.2.16.2) Ex vivo experiments 
Co-cultures of T cells and hippocampal slices were used after 24 h of co-culture for two-
photon Imaging. In order to differentiate viable and apoptotic T cells, co-cultures were 
stained with Image-iT ™ LIVE Red Caspase-3 and -7 Detection Kit prior to imaging. Thus, 1x 
wash buffer was prepared by diluting 1 part warm 10x apoptosis wash buffer with 9 parts 
deionized H2O. A 30-fold dilution of 30x FLICA reagent working solution was prepared in cell-
culture medium, mixed well, and added on top of the slice. This was followed by incubation 
for 30-60 minutes at 37 °C in a 5 % CO2 atmosphere and 95 % humidity in the dark, as 
enabled by the use of cell culture incubators. Subsequently, the solution was removed and 
the slice was gently rinsed with 2 mL of 1x wash buffer. 
For imaging, the cell culture inserts with the organotypic hippocampal slices were 
transferred to 60 mm cell culture dishes. The cell culture dishes were then transferred onto 
the stage of a Leica TCS-MP5 multi-photon system with a heated and gas perfused 
(95 % O2/5 % CO2) Ludin enclosure. Volumes of 300 µm x 300 µm at variable depth (max. 
80 µm) were acquired with a Leica HCX IRAPO L 25x/0.95 W objective, at 1000 nm to 
visualize the interaction between CX3CR1.GFP microglia and 2D2.RFP Th17 cells. LIF files 
were exported for analyses. For imaging CX3CR1.GFP microglia and 2D2.CFP.Th17 cells that 
were alive (blue) or stained with Image-iT® LIVE Red Caspase-3 and -7 (red), as well as for 
imaging long term (beyond 20 min), the TriMScope I from LaVision Biotec with the Bold-Line 
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series of stage top incubators from Okolab was used, allowing long uninterrupted imaging 
while keeping tight control of temperature, humidity and atmospheric gases. 
2.2.17) Two-photon imaging analysis 
All image analysis was performed using Imaris software. Cell tracks were created using the 
tracking tool and manually corrected. Contact types and durations were determined 
manually with 3D rotation and surface analysis to verify contacts. Temporary contacts were 
defined as contacts lasting less than 10 min, stable contacts consisted of contacts lasting 
longer than 10 min. Engulfment processes (EPs) were subdivided in engulfment (T cell is fully 
surrounded by the microglial cell), escape (T cell moves through the microglial cell) and clear 
attempt to engulf (microglia actively prolongs processes to engulf microglia). Noise 
reduction was achieved using the software’s “medium filter”. 
2.2.18) Immunohistochemistry 
Immunohistochemistry was performed with co-cultures of organotypic hippocampal slices 
from CX3CR1.GFP mice with 2D2 T cells (2.2.15). Therefore, the slices were first fixated by 
transferring the slice culture inserts to a 6-well plate containing 1 mL PFA (4 %). 1 mL 
additional PFA (4 %) was added on top of the slice. Incubation occurred for 20 min at RT. PFA 
was removed and the fixation step was repeated two times using fresh PFA (4 %) to 
complete fixation. The slices were then washed with phosphate buffer (PB) three times 
(each time 20 min at RT), before the slices were cut out of the insert membrane using a 
scalpel. The cut culture insert was glued onto a block of agarose to enable re-slicing of the 
slices with a vibratome. The agarose block was glued to a metal plate which was submerged 
in the PB-water (1:1) bath of the vibratome cooled to 4 °C. Using the vibratome, the original 
slices were re-sliced into 50-µm-thick slices. These slices were transferred to Netwell inserts 
(74 µm mesh size) for free-floating immunohistochemistry and either stored in PB at 4 °C or 
directly used for the immunostaining. 
Before immunostaining was started, non-specific binding sites were blocked using a serum 
blocking buffer containing NGS (5 %) and Triton X-100 (0. 2 %) diluted in PB. Therefore the 
slices were incubated in 1 mL of this blocking buffer for 1 h. This incubation step and all 
subsequent incubation steps were performed in the dark on a platform shaker. To stain 
microglia, 1 mL of a staining solution containing a primary anti-mouse GFP antibody (rabbit) 
at a dilution of 1:500 in PB with 0.1 % Triton X-100 were applied and incubated at 4 °C 
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overnight. The staining solution was then removed and the slices were washed 3 times with 
PB (each time 10 min). The fluorophore-conjugated secondary antibody anti-rabbit-AF488 
was then added at a concentration of 1:1000 in PB containing 0.1 % Triton X-100 and 
incubated at RT for 4 h. The staining solution was removed and the slices were washed 3 
times with PB (each time 10 min). To stain CD4+ cells, 1 mL of the fluorescently labeled 
primary antibody anti-mouse-CD4-AF647 (1:200) were added in PB containing 0.1 % Triton X-
100 for 4 h. Subsequently, the staining solution was removed and the slices were washed 
with PB (10 min). To stain the nucleus DAPI was used at a concentration of 500 ng/mL in PB 
and incubated for 20 min at RT. Following incubation, slices were washed five times with PB 
for 7 min at RT. The slices were then mounted on microscope glass slides using ProLong Gold 
Antifade Mountant. The Confocal Laser Scanning System SP8 from Leica was used to acquire 
images which were exported as TIFFs for analysis in ImageJ or Imaris software. 
2.2.19) Statistical analysis 
If not otherwise mentioned, all data were analyzed using GraphPad Prism 6. Mean group 
differences were investigated by one-way ANOVA followed by Tukey’s multiple comparison 
test, Mann-Whitney test or independent-sample t-tests. Significance level was set at 0.05. 
The ROUT method implemented in GraphPad was used to identify and exclude outliers. For 
slice culture experiments, pie charts reflect the mean of the relative interaction distributions 
per analyzed video. If normalization was performed in slice culture experiments, each 
parameter was normalized to the mean of the control group from the respective slice 
preparation.
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3) Results 
3.1) Increase of alternatively activated antigen myeloid cells (aaMC) in active EAE 
In order to understand how activated myeloid cells are involved during different phases of 
EAE, CD11c+ myeloid cells were isolated from the CNS and the spleen of SJL/J and C57BL/6 
mice at different time points during the disease using flow cytometry (Figure 4). For this, up 
to seven mice with a clinical score representing the mean clinical score of the entire group 
were combined to gain enough cells for the gene expression analysis during the different 
disease states using RNA-Seq. SJL/J mice were used to analyze the gene expression of 
myeloid cells during exacerbation, remission, and relapse phase of the disease. Gene 
expression in myeloid cells from C57BL/6 mice was analyzed on day 15 prior to the 
 
Figure 4: Isolation strategy of CD11c+ myeloid cells during EAE. (a+b) Clinical symptoms of SJL/J mice 
immunized with PLP139-151 (a) and C57BL/6 immunized with MOG35-55 (b) are shown. Data represent the 
mean clinical score of three independent EAE experiments. CD45+CD90-CD11c+ myeloid cells (SJL/J) or 
CD45+CD90-CD11c+MHCII+ myeloid cells (C57BL/6) from the CNS and spleen were isolated at the 
exacerbation of the disease, (partial) remission and relapse, as marked with arrows. (c+d) Exemplary gating 
strategy for the isolation of CD45+CD90-CD11c+MHCII+ myeloid cells from CNS (c) and spleen (d). 
CD45+CD90-CD11c+MHCII+ myeloid cells were sorted by flow cytometry from CD11c+ cells pre-enriched 
using bead based cell sorting. Debris, doublets, and dead cells were excluded according to the forward and 
sideward scatter properties of the cells, and using PI. CD45+CD90-CD11c+MHCII+ cells were gated using 
fluorescent-labeled antibodies. Plots represent sorting from combined C57BL/6 animals. 
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exacerbation of the disease, when clinical scores were comparable to scores during partial 
remission. Thus, differences in gene expression in cells isolated from C57BL/6 mice should be 
related to disease states rather than to differences in the clinical score (Figure 4b). 
3.1.1) Gene expression during exacerbation and remission is strain specific 
A principal component analysis (PCA) based on the variance-stabilized expression data of the 
100 most variable genes was performed to identify the main sources of expression variation. 
The first two principal components (PCs) PC1 and PC2 visualized a clear separation of CNS 
and spleen samples along the PC1 axis and of SJL/J and C57BL/6 samples along the PC2 axis 
(Figure 5). These data clearly identified the genetic background and the organ tissue as the 
main sources of variation in gene expression which was much stronger than the additional 
gene expression variations comparing the different disease states in the CNS. However, CNS 
samples collected during remission in SJL/J mice seemed to form a cluster which appeared to 
be distinct from the cluster of exacerbation samples, confirming the expectation of a gene 
expression regulation during the distinct disease states. In C57BL/6 mice no clearly 
separated cluster for exacerbation and partial remission samples was observed. It was of 
interest, which genes were differentially expressed in both mouse models comparing the 
exacerbation state and the remission despite the strong genetic differences. 
  
Figure 5: Expression variability depends on mouse strain and target organ. Scores of the RNA-Seq libraries 
generated from CD11c+ myeloid cells on the two principal components (PC1, PC2) that capture the highest 
amount of expression variability. The PCs are derived from a PCA conducted on the 100 genes with highest 
expression variation in the RNA-Seq libraries. Each dot corresponds to one RNA-Seq library generated from 
3-7 pooled mice from a single experiment. The statistical analyses of RNA-Seq data were performed in 
collaboration with the Institute of Medical Biostatistics Epidemiology and Informatics of the Johannes 
Gutenberg University Medical Center in Mainz, Germany. 
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3.1.2) Genes characterizing aaMC are regulated during EAE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Comparable regulation of gene expression during EAE in SJL/J and C57BL/6 mice show 
importance of aaMC markers. (a) Gene expression measured by RNA-Seq in CD11c+ myeloid cells isolated 
from the CNS of SJL/J mice during the exacerbation and during the remission of the disease is shown for 
significantly regulated genes (likelihood- ratio test, FDR < 5%). The results of three independent RNA-Seq 
experiments are shown. The gene expression data was z-transformed after the variance was stabilized. 
Relative expression is indicated by color intensity. Green indicates lower while red indicates higher 
expression compared to the mean expression across all samples. The horizontal dendrogram indicates the 
relationship between the different samples based on their expression levels inferred by hierarchical 
clustering. The vertical dendrogram indicates the relationship between genes based on their expression 
levels inferred by hierarchical clustering. (b+c) The log2 fold-change (logFC) between exacerbation and 
remission of EAE diseased SJL/J mice (b) and C57BL/6 mice (c) is shown relative to average expression levels 
(Mean expression (log2 counts per million (CPM)) inferred from each three independent experiments. 
Positive fold changes indicate higher, negative fold changes indicate lower expression in the exacerbation 
compared to remission. Significantly regulated genes (likelihood- ratio test, FDR < 5%) are labeled in 
magenta. Selected genes that are found differentially expressed between exacerbation and remission in 
SJL/J mice (see a) are labeled in blue. The statistical analyses of RNA-Seq data were performed in 
collaboration with the Institute of Medical Biostatistics Epidemiology and Informatics of the Johannes 
Gutenberg University Medical Center in Mainz, Germany. 
a b 
c 
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Gene expression analysis of CD11c+ myeloid cells isolated from the CNS of SJL/J mice during 
the different disease states revealed 36 genes to be differentially expressed comparing 
exacerbation and remission (Figure 6a+b and Table 1). Fewer differences were found 
between exacerbation and relapse, or remission and relapse (Figure 7). Genes which were 
significantly regulated in SJL/J mice comparing exacerbation and remission were considered 
as genes of interest (Figure 6, Figure 7, marked in blue). Here, genes coding for antibody 
immunoglobulin chains originating from CD11c+ B cells (Figure 6a and Table 1) were 
Table 1: Statistical analysis of RNA sequencing of CNS samples from EAE diseased SJL/J mice. Significantly 
regulated genes comparing exacerbation and remission of disease are shown. Logarithmic fold-change 
(logFC)(base2), logarithmic counts per million reads (logCPM), p values, FDR and total read counts for 
exacerbation, remission and relapse are reported for three experimental repeats. The statistical analyses of 
RNA-Seq data were performed in collaboration with the Institute of Medical Biostatistics Epidemiology and 
Informatics of the Johannes Gutenberg University Medical Center in Mainz, Germany. 
Gene logFC logCPM PValue FDR  
Ms4a8a 4.8 4.3 1.73E-08 4.77E-05 
Genes more highly 
expressed during 
exacerbation of 
disease 
Arg1 5.1 8.6 1.66E-07 3.27E-04 
Chi3l3 4.7 9.4 3.28E-06 3.68E-03 
Ecm1 3.0 6.2 8.90E-06 8.01E-03 
Nt5e 3.3 4.1 1.33E-05 1.08E-02 
Kazald1 7.5 1.8 6.82E-05 3.25E-02 
Slc36a2 4.9 2.3 0.000125 4.80E-02 
Igkv6-23 -6.1 3.9 3.63E-09 2.89E-05 
Genes more highly 
expressed during 
remission of disease 
Igkc -4.1 7.4 4.18E-09 2.89E-05 
Igj -4.7 5.4 7.94E-09 3.66E-05 
Ighg1 -11.3 5.2 1.47E-08 4.77E-05 
Il2rb -4.0 3.2 1.08E-07 2.49E-04 
Hspa1b -3.2 3.9 2.70E-07 4.66E-04 
Ighg2b -6.0 7.1 3.09E-07 4.74E-04 
Ighv5-6 -10.1 3.3 1.30E-06 1.80E-03 
Hspa1a -2.6 5.8 3.28E-06 3.68E-03 
Mgl2 -2.1 6.0 3.46E-06 3.68E-03 
Il12b -2.2 5.7 7.09E-06 7.00E-03 
Ighg2c -4.5 4.2 9.28E-06 8.01E-03 
Igkv6-20 -10.0 3.5 1.46E-05 1.12E-02 
Ighv4-1 -8.5 2.5 1.56E-05 1.13E-02 
Ighv1-55 -7.3 2.3 1.72E-05 1.19E-02 
Igkv1-117 -7.7 2.0 1.89E-05 1.24E-02 
Hist1h2be -4.7 1.8 2.57E-05 1.61E-02 
Ighv8-8 -6.8 0.5 2.89E-05 1.73E-02 
Treml4 -3.4 3.7 4.38E-05 2.52E-02 
Igha -2.8 3.6 5.13E-05 2.83E-02 
Prr11 -4.9 1.3 6.25E-05 3.25E-02 
Clec9a -2.3 5.4 6.55E-05 3.25E-02 
Xcl1 -5.3 1.5 6.65E-05 3.25E-02 
Tanc2 -2.5 4.2 7.20E-05 3.32E-02 
Igkv3-5 -7.8 1.2 8.32E-05 3.65E-02 
Klrc1 -6.7 0.6 8.46E-05 3.65E-02 
Tmem150c -3.2 2.4 0.000105 4.38E-02 
Tnni2 -2.1 3.9 0.000117 4.75E-02 
Igkv9-120 -7.3 1.6 0.000125 4.80E-02 
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excluded from further analysis. Comparing the gene expression regulation of the genes of 
interest between SJL/J and C57BL/6 mice revealed uniquely Ms4a8a to be significantly 
regulated in both mouse models (Figure 6a-c). Of note, Ms4a8a, Chi3l3 (YM1) and Arginase1, 
reached the highest significance and the highest fold changes in SJL/J mice (Table 1 and 
Figure 6a+b) and although not significantly, YM1 and Arginase1 were regulated similarly in 
C57BL/6 mice (Figure 6c). Interestingly, Ms4a8a, YM1 and Arginase1 were all described as 
markers for aaMC (Munder et al., 1998; Raes et al., 2002; Schmieder et al., 2012) and the 
simultaneous upregulation in the exacerbation suggests a role of this myeloid cell subset 
during the exacerbation of disease. Tracking Ms4a8a, YM1 and Arginase1 over the disease 
course in SJL/J mice revealed a reduced expression also during relapse compared to 
exacerbation (Figure 7a). The same genes showed a trend towards a lower expression during 
remission than during relapse (Figure 7b), demonstrating a regulation of these gene 
expressions over the whole disease course. In the spleen, a significantly lower expression of 
all three genes was detected compared to CNS suggesting an active role of the respective 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7: Genes of interest are regulated over the whole disease course. The log2 fold-change (logFC) 
between gene expression measured by RNA-Seq in CD11c+ myeloid cells isolated from the CNS during 
exacerbation and relapse (a) and remission and relapse (b) of EAE diseased SJL/J is shown relative to 
average expression levels (Mean expression (log2 counts per million (CPM)) inferred from each three 
independent experiments. Positive fold changes indicate higher, negative fold changes indicate lower 
expression. Significantly regulated genes (likelihood- ratio test, FDR < 5%) are labeled in magenta. Genes of 
interest are labeled in blue. The statistical analyses of RNA-Seq data were performed in collaboration with 
the Institute of Medical Biostatistics Epidemiology and Informatics of the Johannes Gutenberg University 
Medical Center in Mainz, Germany. 
a b 
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proteins in the target organ of the disease (Figure 8). These results were independent of the 
mouse strain as both SJL/J mice (Figure 8a) and C57BL/6 mice (Figure 8b) showed a 
significantly lower mRNA expression of all three genes in the spleen.  
To confirm the sequencing data, mRNA expression of CD11c+ myeloid cells from the CNS and 
spleen of EAE diseased mice were additionally analyzed using qRT-PCR. Taking advantage of 
this technique, gene regulation of Ms4a8a (Figure 9a+d), YM1 (Figure 9b+e) and Arginase1 
(Figure 9c+f) was confirmed in the CNS of both SJL/J and C57BL/6 mice. The most prominent 
expression of Ms4a8a, YM1, and Arginase1 was again found during the exacerbation of the 
disease, while during remission and relapse a reduced expression of Ms4a8a and YM1 was 
detected. Although not significantly, Arginase1 showed a slight increase in expression during 
relapse after remission, as also suggested by the RNA-Seq data, showing the strongest 
regulation of Arginase1 comparing the three markers of alternatively activated macrophages 
during remission and relapse (Figure 7b). These data indicate a more prominent role of 
Arginase1 in relapses as compared to Ms4a8a and YM1. 
 
 
 
 
 
 
 
 
 
 
  
Figure 8: aaMC markers are more highly expressed in the CNS compared to the spleen during the 
exacerbation of EAE disease. The log2 fold-changes (logFC) between gene expression measured by RNA-
Seq in CD11c+ myeloid cells isolated from the CNS and spleen during exacerbation of EAE diseased SJL/J (a) 
and C57BL/6 mice (b) are shown relative to average expression levels (Mean expression (log2 CPM)) 
inferred from three independent experiments. Genes of interest are labeled in blue. Positive fold changes 
indicate higher, negative fold changes indicate lower expression in the CNS compared to spleen during 
exacerbation of disease. Significantly regulated genes (likelihood- ratio test, FDR < 5%) are labeled in 
magenta. The statistical analyses of RNA-Seq data were performed in collaboration with the Institute of 
Medical Biostatistics Epidemiology and Informatics of the Johannes Gutenberg University Medical Center in 
Mainz, Germany. 
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Figure 9: Expression of Ms4a8a, YM1 and Arginase1 genes is higher in myeloid cells from the CNS during 
the exacerbation of EAE compared to other disease states. qRT-PCR was performed with cDNA from 
CD45+CD90-CD11c+MHCII+ myeloid cells isolated from the CNS and from the spleen during the exacerbation, 
(partial) remission and relapse of the EAE in SJL/J (a-c) and in C57BL/6 mice (d-f). Data represent the 
expression of Ms4a8a (a,d), YM1 (b,e) and Arginase1 (c,f) in 4–9 samples normalized to β-actin expression. 
Horizontal lines indicate mean and standard error of the mean (SEM). Differences in gene expression 
between disease states was investigated by one-way ANOVA and Tukey’s multiple comparison test; ns = not 
significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
a 
b 
c 
d 
e 
f 
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In the spleen, all markers showed lower or no expression and no significant regulation of 
Ms4a8a, YM1 or Arginase1 mRNA expression was detected tracking the disease course 
(Figure 9). 
In order to confirm a role of these genes upon alternative activation of myeloid cells, the 
induction of Ms4a8a, YM1 and Arginase1 gene expression was further investigated in in 
vitro-generated mouse BMDM and BMDC via treatment with LPS/Dexamethasone/IL-4 for 
72 h, which has been previously described to cause an alternatively activated phenotype of 
myeloid cells (Schmieder et al., 2012).  
Treatment with LPS/Dexamethasone/IL-4 induced Ms4a8a, YM1 and Arginase1 gene 
expression in BMDM (Figure 10a-c) and Ms4a8a and YM1 (Figure 10d+e) but not Arginase1 
(Figure 10f) gene expression in BMDC as determined by qRT-PCR. Thus, generally both 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 10: Ms4a8a, YM1 and Arginase 1 expression in BMDM and BMDC following LPS/IL-4 and 
dexamethasone exposure. BMDMs (a-c) and BMDCs (d-f) were treated for 72 h with either LPS (10 µg/mL) 
or a combination of LPS (10 µg/mL), IL-4 (10 ng/mL) and Dexamethasone (5 x 10-7 M). RNA expression of 
Ms4a8a, YM1, and Arginase1 was analyzed by qRT-PCR and normalized to β-actin expression. Data 
represent the expression of Ms4a8a (a, d), YM1 (b, e) and Arginase1 (c, f) of 10–13 samples from each of 
four experimental repeats for BMDMs and BMDCs. Horizontal lines indicate mean and SEM. Significance of 
difference in mean expression was assessed using an unpaired t-test; ns = not significant, *** = p < 0.001, 
**** = p < 0.0001. 
a b c 
d e f 
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macrophages and dendritic cells were able to contribute to the higher Ms4a8a and YM1 
expression during the exacerbation. However, the gene expression of aaBMDM fit best with 
the genes found in ex vivo myeloid cells during the exacerbation. 
3.1.3) Disease state correlates with expression of aaMC markers  
To investigate whether the observed higher expression of Ms4a8a, YM1 and Arginase1 in the 
CNS during the exacerbation of the disease was dependent on the disease phase rather than 
  
Figure 11: Correlation of aaMC marker expression with clinical score dependent on disease state. qRT-PCR 
was performed with cDNA from CD45+CD90-CD11c+MHCII+ myeloid cells isolated from the CNS of mice 
varying in clinical score during the exacerbation, remission and relapse of EAE. Dots represent the 
expression of Ms4a8a (a), YM1 (b) and Arginase1 (c) normalized to -actin expression in samples of 1–7 
pooled animals, relative to the mean clinical score of all pooled animals. Linear regression was employed to 
visualize correlation of gene expression with clinical scores separately for the different disease states (solid 
lines). 
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on the clinical score, the expression levels of Ms4a8a, YM1 and Arginase1 were determined 
in relation to the clinical scores. This analysis clearly demonstrated no correlation between 
the gene expression and the clinical score, neither during the different unique disease states 
nor when analyzing the data set as a whole (Figure 11). Even if equal scores were compared 
during exacerbation and relapse in SJL/J mice (Figure 11), expression of Ms4a8a, YM1 and 
Arginase1 genes was higher during the exacerbation compared to the relapse state. This may 
indicate that the activity of Ms4a8a, YM1 and Arginase1 genes counteracted autoimmune 
inflammation during the first disease wave independent on the disease severity. In order to 
deeply analyze the function of CNS resident myeloid cells during the active disease state, 
two-photon imaging was applied to visualize direct microglia-T cell interactions in the CNS.  
3.2) Fate of living Th17 cells engulfed by microglia in neuroinflammation  
In vivo two-photon imaging is a powerful tool in neuroimmunological research that enables 
 
Figure 12: Visualization of microglia-T cell interactions in the CNS in vivo.  Naïve T cells were isolated from 
2D2.RFP mice and skewed into Th17 cells. These pathogenic T cells were injected i.v. into 
B6.CX3CR1.GFP.Rag mice (either homozygous or heterozygous for GFP and Rag) to induce EAE. The 
interactions of fluorescently labelled T cells (red) and microglia or other CX3CR1+ cells in the CNS (green) 
were visualized using two-photon (2PH) microscopy during distinct disease severities, allowing the video-
preparation of live-interactions as well as the analysis of those interactions. 
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the direct assessment of disease processes and cellular interactions in the intact CNS tissue 
(Kawakami and Flügel, 2010; Weigert et al., 2010). In order to analyze the function of CNS 
resident myeloid cells during the active disease state more precisely, two distinct platforms 
to investigate microglia-T cell interactions in the CNS were established in this study. In one 
approach, two-photon imaging was performed in vivo in EAE-diseased animals to allow the 
direct investigation of disease state-dependent processes (Figure 12). Therefore EAE was 
induced by transfer of pathogenic red-fluorescent MOG35-55 peptide-specific Th17-skewed 
 
Figure 13: Visualization of microglia-T cell interactions in organotypic hippocampal slices.  Naïve T cells 
were isolated from 2D2.CFP mice, skewed into Th17 cells and co-cultured with organotypic hippocampal 
slices (7-14 days cultured). Optional pre-treatment of the hippocampal slices was performed 24h before co-
culture was started. Co-culture treatment was performed when starting the co-culture. Apoptotic cells 
were labeled after 24h of co-culture (30 min prior to imaging) with a Caspas3/7 red-staining. The 
interactions of fluorescently labeled viable T cells (blue) and microglia (green) and apoptotic cells (red) with 
microglia (green) were visualized using two-photon (2PH) microscopy, allowing the video-preparation of 
live-interactions as well as the analysis of those interactions. 
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cells (2D2.RFP) into recipient mice. To enable microglia visualization, EAE was induced in 
B6.CX3CR1.GFP.Rag recipient mice (either homozygous or heterozygous for GFP and Rag), in 
which the expression of GFP is driven by the CX3CR1 promoter. Thus, microglia, which have 
been shown to express CX3CR1 (Goldmann et al., 2013; Jung et al., 2000), were labeled in 
green and T cells were visualized in red, allowing the investigation of microglia-T cell 
interactions via two-photon microscopy. In a separate approach, organotypic hippocampal 
slices (Stoppini et al., 1991) were used to allow targeted modification processes in a stable 
ex vivo model (Figure 13). Organotypic hippocampal slice cultures develop largely similar to 
the in vivo tissue, especially when pups around P5 are selected for slicing (De Simoni et al., 
2003; De Simoni and My Yu, 2006). After one week in vitro, most cells in the slice surface are 
healthy, receiving and sending inputs from intact axons, thus enabling high-resolution 
imaging under in vivo-like conditions while having the possibility of precise experimental 
intervention (De Simoni and My Yu, 2006). Here, these hippocampal slices were prepared 
using B6.CX3CR1.GFP pups in which microglia were labeled in green (Jung et al., 2000). The 
hippocampal slices were cultured for 7-14 days to allow microglial stabilization after cutting-
mediated tissue damage (Vinet et al., 2012) before they were used for further experiments. 
Blue-fluorescent T cells were then cultured with the hippocampal slices to mimic the in vivo 
situation and T cell infiltration under stable conditions. In addition to the advantages of a 
stable, targetable system, this ex vivo model enabled the specific visualization of microglia, 
since CNS-infiltrating CX3CR1+ myeloid cells which are present in the CNS under EAE 
conditions (Geissmann et al., 2003; Goldmann et al., 2013; Jung et al., 2000) should be 
barely present in hippocampal slices prepared from healthy pups. Similar to the in vivo 
model, the fluorescently labeled cells allow the visualization of cellular interactions via two-
photon imaging. The exclusive excitation of molecules in the laser focus, the protection of 
the surrounding tissue from bleaching, and a deep penetration into the tissue reflect major 
advantages of two-photon microscopy compared to other microscopic approaches (Denk et 
al., 1990; Theer et al., 2003; Zipfel et al., 2003).  
3.2.1) In vivo imaging reveals engulfment of viable T cells by microglia in neuroinflammation 
To understand how microglia react towards a T cell-driven CNS inflammation, the dynamic 
interactions of microglia and T cells were visualized in the upper brainstem, which is highly 
affected by T cell infiltration and inflammation during EAE (Siffrin et al., 2015; Siffrin et al., 
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2010a). Infiltrating pathogenic T cells in EAE lesions were found to intensely interact with 
CX3CR1.GFP cells. In-depth analyses of the surface-reconstructed images revealed multiple 
types of interactions, including full engulfment of the CNS-infiltrating pathogenic Th17 cells 
by CX3CR1.GFP microglia (Figure 14a-d). Remarkably, two different T cell fates were 
observed after uptake by microglia. T cells either stayed engulfed or were able to escape this 
engulfment. These observations point to an active attempt of the CNS-resident microglia to 
remove invading T cells, although these attempts were only partially successful in the 
inflamed CNS due to the ability of pathogenic T cells to regularly escape from microglia 
engulfment.  
3.2.2) Resident myeloid cells are responsible for engulfment processes - intravital two-photon 
imaging in organotypic slice cultures   
To exclude a possible contribution of CNS-infiltrating CX3CR1.GFP myeloid cells under EAE 
conditions (Geissmann et al., 2003; Goldmann et al., 2013; Jung et al., 2000), organotypic 
hippocampal slice cultures prepared from CX3CR1.GFP mice were co-cultured with 
  
 
 
 
 
 
 
 
 
 
 
Figure 14: Viable T cells in EAE lesions can be engulfed in vivo by CX3CR1+ cells without subsequent cell 
death. EAE was induced in CX3CR1.GFP (microglia green) mice via the passive transfer of 2D2.RFP.Th17 cells 
(red). At the peak of disease, approximately 11 days post immunization, interactions were imaged in vivo 
with intravital two-photon imaging and analyzed using 3D reconstruction software Imaris. (a) Time-lapse 
surface analysis of the full engulfment (min 3 and 4) of a red fluorescent Th17 cell by a green microglial cell, 
followed by the escape from this engulfment (min 5-10). Scale bars = 10 µm. (b-d) Magnified and 3D-
rotated surface analysis of the sequence from (b) full engulfment and (c) escape to (d) full T cell 
detachment. Scale bars = 15 µm. 
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pathogenic T cells for 24 hours, allowing to exclusively focus on microglia-T cell interactions 
in a controlled ex vivo setting, mimicking the in vivo condition. As mentioned above, in the 
hippocampus of healthy, non-immunized CX3CR1.GFP mice, CX3CR1+ infiltrating myeloid 
cells should be absent or only barely present. In the resulting two-photon time-lapse movies, 
the observation that microglia cells readily engaged and engulfed T cells in vivo, was 
confirmed (Figure 15). The engulfment of CD4+ T cells was further confirmed via 
immunohistochemistry (Figure 16). Based on these detailed observations (Figures 15+16), 
five different types of microglia-T cell interactions were defined: “Temporary” (less than 10 
minutes of continuous contact) and “stable” (at least 10 minutes of continuous contact) 
contacts were most common. In addition to the already described “engulfments” and 
“escapes” from engulfment following a migration through the microglial cytoplasm (Figure 
14), the active prolongation of microglial extensions towards and around T cells, either 
successfully or not (“engulfment attempts”), was also observed (Figure 15). These three 
engulfment-related interactions were summarized under the term “Engulfment Processes” 
(EPs) (Figure 15).  
Figure 15: Various interactions 
between microglia and T cells can be 
observed in hippocampal slice 
cultures. 24 h co-cultures of 
organotypic hippocampal slices from 
CX3CR1.GFP pups with pathogenic 
2D2.RFP.Th17 cells were imaged over 
a time period of 10 min. The 
characterization of all detectable 
interactions between microglia 
(green) and T cells (red) is shown. All 
interactions in which a T cell was 
engulfed, crossing the cytoplasm of a 
microglial cell during the interaction 
or in which a microglial cell prolonged 
it’s processes in order to engulf a T 
cell (Engulfment, Escape and 
Engulfment attempt) were 
summarized under the term 
Engulfment Processes (EPs). Scale 
bars = 15 µm.  
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3.2.3) The interactions of T cells and microglia are regulated over the disease course 
The defined interactions between microglial cells and T cells were not static, but depended 
on the disease severity (Figure 17). While the percentage of stable contacts increased in 
correlation with a higher disease score, temporary contacts were more abundant at lower 
disease scores (Figure 17a+b). Interestingly, the full engulfment of pathogenic T cells was 
found to be more prevalent in the CNS of EAE-diseased mice exhibiting a low clinical score 
(Figure 17a+b). In the same sense, the T cell motilities were altered over the disease score. 
Corresponding with the higher amount of temporary contacts compared to stable contacts 
during a less severe EAE phase, the T cell motility parameters “T cell speed” and “T cell 
displacement rate” were found to be higher in EAE-diseased mice exhibiting a clinical score 
below 2 as compared to mice exhibiting a clinical score above 2 (Figure 17c+d). Similar 
results were obtained analyzing the T cell infiltration and migration capacities during the 
different disease states (Figure 17e). During early phases of the disease, T cells showed a 
higher migration compared to disease states in which a higher disease score was reached 
(Figure 17e). 
The interactions of microglia and T cells in organotypic hippocampal slice cultures showed 
comparable distributions to the interactions of microglia and T cells in the CNS of EAE-
diseased mice exhibiting a low clinical score (Figure 17b). In terms of T cell motility, T cells in 
organotypic hippocampal slice cultures showed intermediate T cell motility parameters as 
compared to T cell motilities in mice exhibiting a clinical score either above or below 2 
(Figure 17d). The T cell infiltration in organotypic hippocampal slice cultures was comparable 
to mice exhibiting a clinical score of 1.5 (Figure 17e). In summary, the hippocampal slice 
cultures represented an appropriate model for the in vivo system during the early (low  
 
Figure 16: Engulfment of T cells by microglial cells is 
confirmed via immunohistochemistry. 24 h co-cultures 
of organotypic hippocampal slices from CX3CR1.GFP 
pups were co-cultured with pathogenic 2D2.Th17 cells 
and immunohistochemical staining of microglia 
(antiGFP, green), CD4+ T cells (antiCD4, red) and cell 
nucleus (DAPI, blue) was performed to visualize 
engulfment ex vivo. Asterisks mark engulfed T cells. 
Scale bar = 30 µm. For better visualization, single 
stainings for one engulfment interaction are shown 
(right panel).  
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Figure 17: Interactions between microglia and T cells are dependent on disease score. EAE was induced in 
CX3CR1.GFPxRag-/- and CX3CR1.GFPxRag+/- mice (microglia green) via the passive transfer of 2D2.RFP.Th17 
cells (red). Interactions between microglia and T cells as well as T cell motility parameters were imaged in 
vivo with intravital two-photon imaging and analyzed using 3D reconstruction software Imaris during 
different disease states. For hippocampal slice culture experiments, co-cultures of hippocampal slices from 
CX3CR1.GFP pups with pathogenic 2D2.CFP.Th17 cells were stained with Image-iT™ LIVE Red Caspase-3 and 
-7 Detection Kit to identify apoptotic cells and only living T cells were included in further analyses. (a) 
Percentages of temporary contacts, stable contacts and engulfments in the CNS of EAE-diseased mice 
depending on disease score. p values indicate whether the slope of linear regression is significantly non-
zero. (n = 8 mice) (b) Mean (± SEM) percentages of temporary contacts, stable contacts and engulfments 
among the detected interactions or the detectable T cell count per region of interest were compared in 
mice exhibiting a clinical score below 2 (n = 2 mice), mice exhibiting a score above 2 (n = 6 mice) and 
hippocampal slice cultures (n = 12 organotypic hippocampal slice cultures). (c) Mean (± SEM) of T cell 
motility parameters in the CNS of EAE-diseased mice in relation to disease score. p values indicate whether 
the slope of linear regression is significantly non-zero (n = 8 mice, 30 T cells per mouse). (d) Mean (± SEM) 
percentages of T cell motility parameters of representative T cells were compared in mice exhibiting a score 
below 2 (n = 2 mice, 30 T cells per mouse), mice exhibiting a score above 2 (n = 6 mice, 30 T cells per 
mouse) and hippocampal slice cultures (n = 13 organotypic hippocampal slice cultures, 17-30 T cells per 
slice). (e) Normalization of all T cell tracks in a representative experiment to a common starting point 
compared in a mouse exhibiting a clinical score of 1.5, a mouse exhibiting a clinical score of 4.5 and a 
hippocampal slice co-culture. Each line represents one individual T cell. 
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clinical score) disease course. In order to investigate the engulfment processes more 
precisely, the hippocampal slice cultures were used for further experiments. 
3.2.4) Dual fate of engulfed living T cells: cell death or escape 
In order to determine the fate of engulfed T cells, long-term imaging of the engulfed T cells 
was performed. To assess the viability of engulfed T cells, Caspase-3/7 activity was stained 
during live two-photon imaging, to allow the distinction between viable and apoptotic cells. 
This approach revealed three types of engulfed T cells: living T cells (CFP-positive), early 
apoptotic T cells (diminished CFP-reporter signal and low Caspase-3/7 expression) and 
apoptotic T cells (Figure 18a). Non-viable cells were expected to lose their genetically-
encoded reporter signal (CFP) due to protein degradation. Indeed, in those T cells that did 
not escape, long-term imaging typically showed a gradual reduction in the CFP fluorescence 
signal, indicating the degradation of these T cells within microglial cells (Figure 18b, false-
 
Figure 18: Th17 cell escape from microglia and cell death within microglia after internalization. Co-
cultures of hippocampal slices from CX3CR1.GFP pups with pathogenic 2D2.CFP.Th17 cells were stained 
with Image-iT™ LIVE Red Caspase-3 and -7 Detection Kit to identify apoptotic cells. (a) Identification of 
viable T cells (blue), early apoptotic T cells (blue and red) and apoptotic/dead cells engulfed by microglia 
(green). Scale bars = 10 µm. (b) Representative sequence of an engulfed Caspase-3/7 negative B6.2D2.CFP 
Th17 cell (viable, false colored in red for better visualization) imaged over a time period of 120 min via two-
photon microscopy ex vivo. Scale bars = 15 µm (c) Representative sequence of an escaped viable T cell 
(false colored in red for better visualization) for 44 min ex vivo. Scale bar = 15 µm. (d) Mean (± SEM) T cell 
motility parameters of viable T cells before (n = 6 cells) and after (n = 6 cells) the interaction with microglia 
during the escape process ex vivo. ns = not significant.  
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colored in red for better visualization). On the other hand, engulfed T cells which were able 
to escape the microglial entrapment did not lose their fluorescence intensity or show any 
indications that the engulfment had an effect on the T cell motility parameters (Figure 
18c+d). Follow-up of these escaped T cells confirmed them to be viable and actively moving 
in the tissue for time periods up to at least 45 minutes after escape (Figure 18c).  
3.2.5) Engulfment of viable cells is not dependent on phosphatidylserine exposure  
Since a reversible expression of the “eat-me” signal phosphatidylserine (PS) on stressed (but 
otherwise viable) cells might already lead to recognition by phagocytic cells (Brown and 
Neher, 2014), it was of interest whether the here observed engulfment of living T cells was 
dependent on PS exposure. In order to analyze the effect of an inhibited PS-signaling, 
Annexin V was applied to co-cultures of organotypic hippocampal slice cultures with 
B6.2D2.CFP.Th17 cells at a concentration of 10 µg/mL. Treatment with high concentrations 
of soluble Annexin V has been described to successfully mask PS-signals (Lu et al., 2011). 
Consistent with the known phagocytic abilities of microglia (Sierra et al., 2013), Caspase-3/7+ 
cells were observed to be more frequently engulfed by microglial cells than viable T cells 
(Figure 19a). However, a detailed quantification of the EPs of living cells showed that the EP 
frequency accounted to 13 % of all interactions between living T cells and microglia 
(Figure 19b). While the treatment with soluble Annexin V significantly reduced both the total 
EPs and the engulfment frequencies of apoptotic cells, it had no effect on the EPs and 
engulfment frequencies of living T cells (Figure 19c-e). These data suggest a PS-independent 
mechanism responsible for the engulfment of viable T cells, in contrast to the PS-dependent 
phagocytosis of apoptotic cells. Moreover, the Annexin V treatment did not impact T cell 
motility parameters (Figure 19f). 
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Figure 19: Engulfment of living T cells. 24 h co-cultures of organotypic hippocampal slices from CX3CR1.GFP 
pups with pathogenic B6.2D2.CFP.Th17 cells were stained with Image-iT™ LIVE Red Caspase-3 and -7 
Detection Kit to identify apoptotic cells and imaged over a time period of 20 min with two-photon 
microscopy. (a) Representative example of the Caspase-3 and -7 staining (red) in 24 h co-cultures of 
organotypic hippocampal slices with B6.2D2.CFP.Th17 cells (blue). Scale bars = 40 µm. (b) The pie chart 
demonstrates the distribution (%) of interaction modes between microglia and viable 2D2.CFP.Th17 cells (n 
= 19 organotypic slices) and the contingency bar reflects the distribution of engulfment, escape and 
engulfment attempt. (c+d) Representative two-photon images of the 24 h co-cultures of the organotypic 
hippocampal slices with B6.2D2.CFP.Th17 cells stained with the Caspase-3 and -7 Detection Kit, with or 
without 10 µg/mL Annexin V treatment (24 h); relevant areas are magnified (right panel); asterisks mark 
apoptotic cells (red, c), hashes mark non-apoptotic T cells (blue, d). Scale bars = 40 µm. (e) Mean (± SEM) 
percentages of engulfment-related process (EPs) (left panel) and full engulfments (right panel) among the 
detectable cell count (viable T cells and apoptotic cells) per region of interest, without (n = 7 organotypic 
slices for viable cells, n = 8 organotypic slices for apoptotic cells) and with Annexin V treatment (n = 11 
organotypic slices for viable cells, n = 8 organotypic slices for apoptotic cells). **: p < 0.01; ***: p < 0.001; 
ns = not significant. (f) Mean (± SEM) T cell motility parameters compared between Caspase-3/7+ and viable 
2D2.CFP.Th17 cells without (n = 10 organotypic slices, 276 T cells for viable cells; n = 8 organotypic slices, 
185 T cells apoptotic cells) and with (n = 12 organotypic slices, 205 T cells for viable cells; n = 8 organotypic 
slices, 171 T cells for apoptotic cells) Annexin V treatment. ****: p < 0.0001; ns = not significant. 
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3.2.6) Engulfment is dependent on T cell activity 
To determine whether antigen-specificity impacts T cell–microglia interactions, MOG-specific 
2D2.Th17 cells and polyclonal B6.Th17 cells were compared (Figure 20). Analyzing the 
interaction modes between these conditions revealed similar EP frequencies among the 
overall interactions with microglia. Furthermore, the engulfment frequency among EPs was 
similar for both conditions. Similar results were obtained comparing Th17 and Th2 cells, 
which represent two distinct T helper cell subtypes with highly dissimilar capacities during 
the disease (s. 1.2). In order to uncover whether T cell activity per se might be a prerequisite 
for microglial recognition, the role of the PI3K/Akt pathway as a major regulator of T cell 
activity was addressed in regard to the engulfment frequencies among the interactions of 
microglia and T cells. PI3K activity was proposed to influence Th17 effector functions (So and 
Fruman, 2012; Wan et al., 2011). Indeed, the PI3K inhibitor Wortmannin downregulated the 
expression of the activation markers CD44 and CD25 in stimulated Th17 cells in vitro (Figure 
21a+b) and  further decreased Th17 cell effector functions as could be shown by a 
significantly lower IL-17 expression in unstimulated and stimulated Th17 cells (Figure 21c). 
Interestingly, Wortmannin treatment was at the same time able to significantly lower the 
engulfment frequency compared to control conditions (Figure 21d-f), indicating an impact of 
the T cell activation status on engulfment probabilities. The reduced engulfment capacity of 
microglial cells was not mediated by a reduced T cell migration into the organotypic 
 
Figure 20: EPs are independent of antigen-specificity and T cell phenotype in organotypic hippocampal 
slices. 24 h co-cultures of organotypic hippocampal slices from CX3CR1.GFP pups with Th17 cells were 
stained with Image-iT™ LIVE Red Caspase-3 and -7 Detection Kit to identify apoptotic cells and imaged over 
a time period of 20 min. Only non-apoptotic T cells were considered for further analyses. Pie charts show 
the distribution (%) of interaction modes between microglia and viable B6.2D2.CFPTh17 cells (Th17 2D2; n = 
19 organotypic slices), polyclonal B6.CFP.Th17 cells (Th17 BL/6; n = 6 organotypic slices) or B6.2D2.CFPTh2 
cells  (Th2 2D2; n = 3 organotypic slices) (upper panel) and contingency bars reflect the respective 
distribution of engulfment, escape and attempt to engulf among EPs (lower panel).  
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Figure 21: Inhibition of Th17 cells activation and cytokine secretion reduces T cell engulfment. (a-c) Th17-
skewed cells (d5 of culture) were either stimulated for 24 h with antiCD3 and antiCD28 or not, each with or 
without the presence of Wortmannin (2.5 µM). Brefeldin A was used during the last 4h of stimulation to 
inhibit secretion of IL-17. (a) Histogram and quantification (mean ± SEM) of CD44 expression among living 
CD4+ T cells. n = 6. (b) Histogram and quantification (mean ± SEM) of CD25 expression among living CD4+ T 
cells. n = 6. (c) Quantification of IL-17 expression among CD4+ T cells (mean (± SEM). n = 6. (d-g) 24 h co-
cultures of organotypic hippocampal slices from CX3CR1.GFP pups with pathogenic 2D2.CFP.Th17 cells were 
stained with Image-iT™ LIVE Red Caspase-3 and -7 Detection Kit to identify apoptotic cells and imaged over 
a time period of 20 min. Only non-apoptotic T cells were considered for further analyses. (d) Representative 
images of organotypic hippocampal slices with pathogenic B6.2D2.CFP.Th17 cells with and without 
Wortmannin (2.5-5 µM) treatment. Asterisks mark engulfed cells. Scale bars = 40 µm. (e) Pie charts show 
the distribution (%) of interaction modes between microglia and viable B6.2D2.CFPTh17 cells without (Th17 
2D2; n = 19 organotypic slices) and with Wortmannin treatment (2.5-5 µM; n = 8 organotypic slices) and 
contingency bars reflect the respective distribution of engulfment, escape and attempt to engulf among EPs 
(lower panel). (f) Relative frequency of engulfment compared to control (Mean ± SEM) among the 
interactions in Wortmannin (2.5-5 µM) treated organotypic hippocampal slices (n = 8 organotypic slices) 
normalized to the untreated control group (n = 5 organotypic slices). (g) T cell motility parameters of viable 
B6.2D2.CFP.Th17 cells without (n = 5 organotypic slices, 141 T cells) and with (n = 8 organotypic slices, 228 T 
cells) Wortmannin treatment (2.5-5 µM; mean (±SEM)). *: p < 0.05, ***: p < 0.001, ****: p < 0.001, ns = not 
significant. 
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hippocampal slice, as PI3K inhibition had no influence on migration properties of Th17 cells 
in the organotypic slices (Figure 21g). Furthermore, Wortmannin had no obvious impact on 
microglia structure or morphology (Figure 21d). 
3.2.7) Microglia activation enhances engulfment of living Th17 cells 
Since the engulfment frequency of T cells was found to be dependent on the activation state 
of T cells, it was of interest whether also the activation status of the microglial cell would 
impact their ability to engulf living T cells. Migration of T cells into the organotypic slice per 
se creates an in vivo-like inflammatory condition. In order to additionally activate microglia 
in organotypic slices, the slices were pre-treated with LPS for 24 h prior to the co-culture of 
the slice with T cells. In parallel to the T cell treatment, fresh LPS was further added to the 
slice. Indeed, EP frequencies significantly increased upon activation via LPS treatment, 
indicating that a marked increase in pro-inflammatory activity of microglia supports 
increased engulfment and thus clearance of invading T cells in neuroinflammation (Figure 
22).  
 
 
Figure 22: EPs are dependent on pro-inflammatory enhancement of microglia activation.  24 h co-cultures 
of organotypic hippocampal slices from CX3CR1GFP pups with pathogenic B6.2D2.CFP.Th17 cells were 
stained with Image-iT™ LIVE Red Caspase-3 and -7 Detection Kit to identify apoptotic cells and imaged over 
a time period of 20 min. Only non-apoptotic T cells were considered for further analyses. (a) The pie chart 
shows the distribution (%) of interaction modes between microglia and viable T cells in LPS (1 µg/mL) 
treated co-cultures of organotypic hippocampal slices with B6.2D2.CFPTh17 cells (n = 9 organotypic slices; 
left panel) and the contingency bar reflects the respective distribution of engulfment, escape and attempt 
to engulf among EPs (right panel). (b) Relative frequency of EP compared to control (Mean ± SEM) among 
the interactions in LPS (1 µg/mL) treated organotypic hippocampal slices (n = 6 organotypic slices) 
normalized to the untreated control group (n = 5 organotypic slices). *: p < 0.05. 
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3.2.8) The engulfment of living T cells is mediated by GlcNAc exposure 
In order to unravel the mechanism of the engulfment of living T cells, the involvement of 
N-Acetyl-D-Glucosamine (GlcNAc), which has been previously discussed as an “eat-me” 
signal on apoptotic thymocytes (Duvall et al., 1985), was examined in this study. Indeed, 
GlcNAc was found to impact the engulfment of living cells (Figure 23). Wheat germ 
agglutinin (WGA) has been reported to bind and detect GlcNAc (Notter and Leary, 1987). 
Using fluorescently labeled WGA, stimulated Th17 cells exhibited an increased binding of 
 
Figure 23: The engulfment of living T cells is dependent on GlcNAc exposure. (a) Th17-skewed cells (d5 of 
culture) were either stimulated with antiCD3 and antiCD28 or not. After 24 h of stimulation WGA binding 
was assessed. A control-staining was performed with unstimulated cells in the presence of GlcNAc 
(200 mM). (b-c) 24 h co-cultures of organotypic hippocampal slices from CX3CR1GFP pups with pathogenic 
2D2.CFP.Th17 cells were stained with Image-iT™ LIVE Red Caspase-3 and -7 Detection Kit to identify 
apoptotic cells and imaged over a time period of 20 min. Only non-apoptotic T cells were considered for 
further analyses. (b) The 24 h co-cultures of organotypic hippocampal slices with Th17 cells were treated 
with GlcNAc (20-40 mM). The pie chart shows the distribution (%) of interaction modes between microglia 
and viable Th17 cells (n = 4 organotypic slices) (upper panel) and the contingency bar reflects the respective 
distribution of engulfment and engulfment attempt among EPs (lower panel). (c) Relative frequency of 
engulfment compared to control (Mean ± SEM) among the interactions in GlcNAc (20 mM) treated 
organotypic hippocampal slices (n = 4 organotypic slices) normalized to the untreated control group (n = 4 
organotypic slices). (d) Th17-skewed cells (d5 of culture) were stimulated for 24 h with antiCD3 and 
antiCD28, with or without the presence of Wortmannin. The quantification of the mean fluorescence 
intensity (mean ± SEM) of WGA binding on stimulated living CD4+ T cells is shown. n = 3. (e) Flow 
cytometric analysis of WGA-binding on living CD4+ T cells in the CNS and spleen of EAE diseased mice in 
actively immunized C57BL/6 mice. (f) Flow cytometric analysis of CD206 in living microglia (PI-GFP+) in 
organotypic hippocampal slices prepared from CX3CR1GFP pups and treated with/without LPS (24 h, 
1 µg/mL) in order to activate microglia. 
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WGA compared to unstimulated cells, indicating that the reduced engulfment rate of 
Wortmannin-treated T cells could be mediated by a lower GlcNAc expression on cells which 
are less activated (Figure 23a).  The binding of WGA could be inhibited by the presence of 
competitive GlcNAc during the staining (Figure 23a). Importantly, the competitive presence 
of GlcNAc in the 24 h-co-culture of organotypic hippocampal slices with Th17 cells affected 
the distribution of interactions and was sufficient to significantly decrease the engulfment of 
T cells by microglia (Figure 23b+c) and Wortmannin was indeed able to reduce WGA-binding 
on activated T cells (Figure 23d). Of note, WGA-binding was higher in T cells invading the 
CNS compared to peripheral T cells in EAE-diseased mice, suggesting a greater importance of 
GlcNAc expression in the target organ of EAE and MS (Figure 23e). Interestingly, the lectin 
CD206, which has been described as a marker for aaMC (Franco and Fernández-Suárez, 
2015), is able to bind GlcNAc (Taylor et al., 1992; Taylor et al., 2005). The data presented 
here show an upregulation of CD206 after LPS-mediated microglial activation in organotypic 
hippocampal slices (Figure 23f) and this microglial activation was accompanied by increased 
engulfment processes (Figure 22). Altogether, the engulfment frequency of pathogenic T 
cells was shown here to be dependent on activity-dependent GlcNAc exposure on T cells. 
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4) Discussion 
Although both beneficial and detrimental roles of myeloid cells have been described during 
EAE and MS in the literature (1.2.1), the gene expression profile which could be primarily 
responsible for the different cell fates was only barely considered, thus demanding a more 
precise and thorough investigation. In this thesis, the gene expression in CD11c+ myeloid 
cells, including resident activated microglia and infiltrated CD11c-expressing dendritic cells 
and macrophages, was extensively analyzed as enabled by mRNA sequencing of the whole 
cell transcriptome. The in-depth analysis of the gene expression profile in CD11c+ myeloid 
cells revealed a list of genes that were regulated analogously in SJL/J and C57BL/6 mice. This 
regulation was stable despite the strong genetic differences and despite substantial 
differences in EAE progression in the two different mouse strains. It was shown for the first 
time that Ms4a8a, YM1 and Arginase1, characterizing aaMC (Munder et al., 1998; Raes et al., 
2002; Schmieder et al., 2012), were the most regulated genes in highly pure CD11c+ CNS 
myeloid cells comparing the exacerbation and remission phases of EAE. Among myeloid 
cells, microglia are CNS-resident and therefore particularly relevant for CNS inflammation. 
Here, microglia were identified for the first time to be able to engulf CNS-invading Th17 cells, 
a process that appeared most prevalent during less severe disease and which could be 
overcome during more severe disease states. This microglial engulfment targeted not only 
apoptotic cells but also fully viable T lymphocytes resulting in stable or temporary cell-in-cell 
structures. The engulfment of viable T cells was determined to be dependent on T cell 
activity, microglial activity and GlcNAc exposure and its success also partially depended on 
the ability of T cells to escape this entrapment. As such, the attempted engulfment of 
microglia may represent a potentially important pathway in MS disease pathogenesis and 
thus its modulation a novel therapeutic target. Overall, this thesis presents new knowledge 
in terms of beneficial myeloid cell involvement during different stages of disease and 
highlights new therapeutic possibilities. 
4.1) aaMC exert beneficial properties during neurological diseases 
In contrast to classically activated myeloid cells (caMC), which seem to worsen EAE and MS 
outcome, aaMC are thought to cause resolution of inflammation, promotion of wound 
healing and therefore to suppress EAE and MS outcome (Jiang et al., 2014). It was shown 
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that the enhancement of aaMC responses during EAE promotes amelioration of the disease 
(Jung et al., 2004; Shin et al., 2000; Tierney et al., 2009). In this context, glatiramer acetate, 
which is approved for the treatment of RRMS, has been shown to enhance the expression of 
immunosuppressive IL-10 in myeloid cells (Jung et al., 2004). Thus, the enhancement of 
aaMC responses represents one of the immunomodulatory mechanisms of glatiramer 
acetate. Of note, the inhibition of iNOS, which is expressed by caMC, has been shown to 
ameliorate EAE disease, while the suppression of EAE development by immune complexes 
was accompanied by elevated IL-10 production in myeloid cells (Shin et al., 2000; Tierney et 
al., 2009). Furthermore, fumarates which are approved for the treatment of MS, have been 
described to influence myeloid cell function and to lead to a shift towards type II polarized 
myeloid cells, favoring Th2 or Treg differentiation (Ghoreschi et al., 2011). The here 
described upregulation of the aaMC markers during the active disease state might thus 
represent an endogenous mechanism to counterbalance CNS inflammation, by an 
endogenous elevation of the aaMC response. Indeed, the high expression of aaMC 
characterizing genes during the first exacerbation state of the disease was followed by a 
reduction of disease symptoms during remission. Pharmacological enhancement of this 
endogenous protective mechanism during chronic disease could thus potentially allow 
amelioration of the disease also in the chronic phase. Of note, other groups observed aaMC 
marker expression in the CNS during further neurological diseases, such as spinal cord injury 
and stroke, emphasizing the great importance of these proteins in the CNS (Hu et al., 2012; 
Schilling et al., 2003; Schwartz, 2010; Shechter et al., 2009). The upregulation of aaMC 
markers might thus reflect a general defense mechanism of microglial cells against CNS 
damage. Therefore, the targeted enhancement of aaMC responses could mediate beneficial 
effects both in MS and in other neurological diseases. In order to specifically target aaMC 
functions and to minimize side effects, it would be desirable to identify the pathways which 
are mainly responsible for the beneficial properties of aaMC. Since the here identified highly 
regulated proteins of aaMC might exhibit great relevance in mediating aaMC responses, 
their impact on aaMC function will be discussed more precisely in the following section. 
4.2) The identified regulated aaMC markers mediate aaMC functions 
Different proteins expressed by aaMC could be crucially responsible for mediating aaMC 
functions. The strong regulation of the three distinct aaMC markers Ms4a8a, YM1 and 
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Arginase1 points to a pivotal role of these genes during the disease in order to mediate 
aaMC function. A disease state-dependent expression of aaMC markers has been described 
previously during spinal cord injury, whereby some aaMC markers were expressed over a 
long time period, but others only temporarily (Kigerl et al., 2009). It stands to reason that 
aaMC markers that are expressed during the active disease state have a strong influence on 
disease progression. Accordingly, the importance of YM1 and Arginase1 during EAE was 
suggested previously. Ahn et al. showed higher expression of Arginase1 during the 
exacerbation of the EAE disease compared to other disease states in total spinal cords of 
diseased Lewis rats (Ahn et al., 2012). Furthermore, the expression of YM1 and other aaMC 
markers was described during EAE (Ponomarev et al., 2007). YM1 expression was both 
detected in resident microglial cells and to a lesser extent in CNS-infiltrating macrophages, 
thus confirming the contribution of both cell types to the aaMC population in the CNS 
(Ponomarev et al., 2007). Considering the protein function of YM1, Arginase1 and Ms4a8a 
more precisely reveals their potential to mediate aaMC properties. Interestingly, it was 
shown that antibody-mediated neutralization of YM1 was sufficient to inhibit Th2 polarizing 
effects of the targeted aaMC in vitro, thus confirming a key function YM1 to mediate aaMC 
responses (Arora et al., 2006). Similarly, Arginase1 plays a decisive role in aaMC, as it serves 
as an enzyme competing with iNOS, the most common marker of caMC, for the substrate L-
arginine and thus reduces NO production (Munder et al., 1998; Rauh et al., 2005). 
Competitive inhibition of iNOS by aminoguanidine has been shown to reduce EAE duration in 
Lewis rats (Shin et al., 2000; Zhao et al., 1996), pointing to the great potential of the 
Arginase1/iNOS competing pathways to influence the disease. However, iNOS and its 
metabolite NO also play a role in various physiological processes such as vasodilation and 
thrombocyte aggregation (Adams et al., 1995), thus again revealing possible targets for 
harmful side effects of shifting the Arginase1/iNOS homeostasis. Of note, Ms4a8a was firstly 
characterized in 2001 by Ishibashi et al. (Ishibashi et al., 2001) and since then has mainly 
been described as a marker for aaMC (Schmieder et al., 2012; Schmieder et al., 2011; 
Weitnauer et al., 2014). Specific targeting of Ms4a8a might thus be accompanied by less 
secondary effects. Although the function of Ms4a8a in aaMC is less well characterized in 
literature compared to YM1 and Arginase1, the here presented results suggest that Ms4a8a 
has a comparable key function in aaMC. In a previous study, forced overexpression of 
Ms4a8a in a macrophage cell line and admixture of these Ms4a8a Raw 264.7 cells 
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significantly enhanced the tumor growth rate of subcutaneously transplanted mammary 
carcinomas (Schmieder et al., 2011). Thus, it appears likely that Ms4a8a promotes an anti-
inflammatory phenotype of CD11c+ myeloid cells as successfully as YM1 and Arginase1, 
which could be in turn beneficial during EAE. Support for this notion comes from remitting 
clinical score soon after the finding that Ms4a8a, as well as Arginase1 and YM1, is strongly 
expressed during the exacerbation of the EAE disease. In summary, Ms4a8a, YM1 and 
Arginase1 reveal new specific target proteins in order to alter aaMC effector functions 
during EAE, whereby especially the effector mechanism of Ms4a8a would merit more 
comprehensive analysis. In order to better understand their role during EAE progression, the 
distribution of aaMC-marker expression comparing the CNS and the periphery will be further 
considered below.  
4.3) Myeloid cells in the CNS show a stronger switch to an anti-inflammatory 
phenotype than peripheral myeloid cells 
Interestingly, highly purified CD11c+ splenic myeloid cells yielded only marginal expression of 
Ms4a8a, YM1 and Arginase1 in the here presented work and the expression of these genes 
was not altered peripherally over the analyzed time points during disease. This underlines 
the particular impact of these genes in the CNS, the target organ in EAE and MS. By contrast, 
a regulation of Arginase1 in peripheral cells has been reported in the past in peripheral 
blood monocytes of Dark Agouti rats, whereby the highest amount of Arginase1 in the 
periphery was found during the exacerbation compared to other disease states (Mikita et al., 
2011). Similarly, flow cytometric analyses of peripheral splenic myeloid cells from EAE-
diseased C57BL/6 mice showed a higher expression of Arginase1 during the disease 
exacerbation which was decreased during the chronic disease state (Liu et al., 2013). 
Nevertheless, both Mikita et al. and Liu et al. reported only marginal expression of Arginase1 
expression in the periphery and an explanation for the different findings observed here 
could be related to the small amounts of these genes in highly purified CD11c+ splenic 
myeloid cells in the current study. Of note, no other study has investigated the 
transcriptome of highly purified activated CD11c+ myeloid cells ex vivo from the CNS of 
diseased animals yet. Taken together, this work and previous works suggest a low expression 
of Arginase1 in the periphery of EAE-diseased mice and an accumulation of Arginase1 
expressing myeloid cells in the CNS during the active disease state. Similar results were 
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obtained in this thesis concerning the Ms4a8a and YM1 expressions which were identified to 
be more highly expressed in the CNS compared to the spleen. These results clearly underline 
the particular impact of myeloid cells in the CNS during EAE and their capacity to adapt their 
phenotype according to the challenges of their environment. There are two main 
explanations for the higher expression of aaMC markers on CNS-infiltrating myeloid cells in 
comparison to the splenic myeloid cells. Either myeloid cells are alternatively activated in the 
CNS or polarization into the alternatively activated state facilitates CNS invasion. 
Importantly, Ms4a8a and YM1 were previously reported to be highly expressed in 
alternatively activated dendritic cells in the lung and this expression was induced by 
bronchial epithelial cells in a glucocorticoid-dependent manner (Weitnauer et al., 2014). 
Weitnauer et al. demonstrated further that both Ms4a8a and YM1 expression was 
significantly increased in the lung compared to the splenic tissue (Weitnauer et al., 2014). 
Interestingly, Flügel and colleagues determined in 2012 that T cells become licensed in the 
lung to enter the CNS (Odoardi et al., 2012). The similar expression profile of aaMC markers 
on myeloid cells in the CNS and myeloid cells in the lung, suggests that also CNS-invading 
myeloid cells could migrate into the lung before entering the CNS, where bronchial epithelial 
cells could promote the expression of aaMC markers on myeloid cells before their invasion 
to the CNS. To validate this, it would be necessary to analyze aaMC marker expression also 
during the disease onset. As of yet, the expression of Ms4a8a and YM1 has been not 
compared during EAE onset and the peak of the disease. However, as described above, the 
aaMC marker Arginase1 was described to be more highly expressed during the peak 
compared to the disease onset (Ahn et al., 2012). These data suggest that another or 
additional pathway in the CNS induces the expression of aaMC markers. In ischemia models 
it has be shown recently that neurons are rapidly able to secrete IL-4 after unilateral 
occlusion of the left middle cerebral artery and the left common carotid artery (Zhao et al., 
2015). This IL-4 production during ischemia was able to induce alternative activation in 
myeloid cells (Zhao et al., 2015). Neuronal damage during MS might thus promote IL-4 
secretion similarly, especially during the exacerbation of the disease. The specific 
upregulation of aaMC markers in the target organ of EAE and MS could thereby reveal a 
protective mechanism, which is directed against damage in the CNS, but not required in 
peripheral organs such as the spleen, where caMC could further promote immune defense 
against pathogens. Of note, EAE was more severe in mice with a CNS deficiency in IL-4 and a 
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higher substantial role of CNS-derived IL-4 was demonstrated compared to peripheral IL-4 in 
order to counterbalance disease progression (Ponomarev et al., 2007). A CNS-internal 
mechanism to induce an alternatively activated phenotype is further necessary to polarize 
CNS-resident microglia. Of note, although both CNS-infiltrating and CNS-resident myeloid 
cells can contribute to beneficial aaMC effects, CNS-resident microglia express the aaMC 
marker YM1 not only during EAE but also – to a lesser extent – in non-diseased mice 
(Ponomarev et al., 2007). Thus, especially microglia, which reside in the CNS tissue during all 
time points of disease development, could mediate aaMC functions from the onset of the 
disease. In order to analyze how myeloid cells in the CNS are able to mediate beneficial 
properties, beside their described aaMC effector functions during the disease, the direct 
reaction of myeloid cells to the infiltration of pathogenic Th17 cells upon EAE was assessed 
here using intravital two-photon microscopy. For this, the focus was specifically directed on 
microglia, the CNS-resident myeloid cells. 
4.4) Beneficial properties of CNS-resident myeloid cells can be mediated via the 
engulfment of invading Th17 cells in the CNS 
It is well known that pathogenic Th17 cells invade into the CNS during MS and EAE, 
mediating inflammation and neuronal degeneration (Dendrou et al., 2015; Goverman, 2009). 
Nevertheless, although microglia were described to continuously scan their environment 
and to mediate both detrimental and tissue homeostatic functions (Heneka et al., 2014; 
Kabba et al., 2017; Nimmerjahn et al., 2005) and even though the great importance of both 
microglia and T cells during EAE and MS is well accepted, direct interactions of microglia with 
Th17 cells within the CNS has been poorly defined as of yet. In this work, intravital two-
photon imaging was used for the first time to characterize microglia-T cell interactions in the 
CNS during EAE in vivo and in organotypic hippocampal slice cultures ex vivo. Two-photon 
imaging is a powerful tool in neuroimmunological research that enables the direct 
assessment of disease processes and cellular interactions in the intact CNS tissue (Kawakami 
and Flügel, 2010; Weigert et al., 2010). Its development enabled the direct observation of 
cellular processes, such as immunologic and neurologic processes, which led to a better 
understanding of elementary processes in immune cell regulation (Cahalan and Parker, 
2008; Herz et al., 2011). Recently it use has broadened our knowledge by investigating 
immune cell trafficking processes (Schläger et al., 2016), the initiation of T-cell mediated 
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neuronal damage (Nikic et al., 2011; Siffrin et al., 2010a) and the role of specific immune cell 
populations such as dendritic cells (Paterka et al., 2016). Taking advantage of this method, it 
was observed in this work that microglia intensely contacted pathogenic Th17 cells in 
inflammatory lesions and that they were able to respond to T cell infiltration by engulfing 
invading T cells. The engulfment process was thereby characterized to be clearly distinct 
from the phagocytosis of apoptotic cells. Unexpectedly, some of these engulfed viable 
pathogenic Th17 cells were able to migrate through the microglia cytoplasm and to escape 
the engulfment, while others underwent cell death. The capture of T cells was dependent on 
GlcNAc expression on T cells and lectin expression on microglial cells. Furthermore, 
engulfment and escape events were independent of antigen presentation or T cell 
phenotype, but did correlate with T cell activity and pro-inflammatory microglia activation 
resulting in increased GlcNAc-lectin interactions. GlcNAc has been discussed previously to 
promote the binding (and subsequent phagocytosis) of apoptotic thymocytes to 
macrophages (Duvall et al., 1985). Of note, the engulfment of viable T cells was found here 
to be not driven by phosphatidylserine exposure, clearly identifying this process as distinct 
from phagocytosis. However, GlcNAc is also expressed by bacteria, where it serves as a 
target molecule for pattern recognition receptors on phagocytes, resulting in the 
phagocytosis and removal of harmful CNS intruders (Nadesalingam et al., 2005; Zhang et al., 
2015). Thus, it seems that microglia aim to remove CNS-invading T cells in a similar process 
as compared to the phagocytosis of CNS-invading pathogens. Taken together, these data 
suggest an active process of microglial cells to remove invading lymphocytes from the brain 
parenchyma. Given these premises, it appears likely that this T cell removal in the CNS 
serves as an additional pathway for microglia to limit inflammation beyond the so far 
reported beneficial effects mediated by the release of anti-inflammatory cytokines such as 
IL-4, IL-10 or TGF-β and the phagocytosis of myelin debris as a prerequisite for tissue 
reengineering (Goldmann and Prinz, 2013). Support for this notion comes from the here 
described observation that microglial engulfment of pathogenic T cells was dependent on 
disease severity. In this sense, it was shown that microglial engulfment was more prevalent 
during early inflammation of mice which exhibited a low clinical score compared to mice 
during chronic disease. Thus, the engulfment of T cells appears to be an early protection 
mechanism of microglial cells, which is overcome during elevated disease states. T cells that 
are able to escape the completed microglial engulfment despite their expression of “eat-me” 
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signals might represent a highly pathogenic subgroup of T cells, critically responsible for EAE 
manifestation. Of note, the capture of pathogenic cells via engulfment processes could be 
not only beneficial in EAE, but also in other diseases. Accordingly, in a mouse model of 
autoimmune hepatitis the engulfment of living T cells by hepatocytes in the periphery has 
been shown to ameliorate disease outcome (Benseler et al., 2011). During EAE, the 
assumption of a beneficial impact of the enhanced microglial engulfment capacities is 
supported by the notion that a high phagocytic capacity of myeloid cells in the CNS has been 
shown to correlate with a faster CNS regeneration (Lampron et al., 2015). The engulfment of 
living T cells might contribute to this beneficial effect. Interestingly, glatiramer acetate, 
which is approved for the treatment of MS, acts on the phagocytic capacity of myeloid cells. 
Monocytes from the blood of patients with MS who received this therapy exhibited 
increased phagocytic activity when compared to those from untreated MS patients or 
healthy controls (Pul et al., 2012). It would be of interest whether glatiramer acetate or 
other therapeutics could also increase the engulfment of living cells and whether this effect 
could contribute to the beneficial effects on disease progression. To allow a better 
understanding of the engulfment processes, it was considered here, how engulfment is 
effected by the microenvironment in the CNS. 
4.5) The microglial engulfment of T cells is dependent on the inflammatory milieu in 
the CNS 
The attempt of microglia to remove non-CNS-resident cells from the brain parenchyma is 
consistent with the previously reported sensing of the CNS parenchyma and the polarization 
of microglial processes into the direction of damage in highly localized laser lesions 
(Nimmerjahn et al., 2005). Indeed, it was confirmed in this work that microglia were highly 
active even in the absence of T cells, continuously extending and retracting their processes 
in search of targets to engulf. Strikingly, LPS, which is known to activate microglia in a TLR4-
dependent manner (Lehnardt et al., 2002), significantly increased the rate of T cell 
engulfment, clearly emphasizing the importance of this process in inflammation. The 
engulfment of living T cells in the CNS may therefore reflect a general defense mechanism of 
the CNS towards invading activated cells. This concept is supported by the fact that 
downregulation of T cell activity by treatment with Wortmannin reduced T cell engulfment 
frequency. Importantly, this was not due to impaired migration of the T cells as the T cell 
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motility parameters were unchanged. Since GlcNAc exposure was higher in T cells isolated 
from the CNS compared to peripheral T cells, it could be possible that either highly activated 
T cells migrate preferentially into the CNS, where they can contribute to the inflammatory 
milieu, or that the inflammatory milieu in the CNS is stimulating GlcNAc exposure on T cells. 
Both possibilities would underline that the inflammatory milieu in the CNS is able to enhance 
engulfment processes during early inflammation. The lectin CD206, which is not only able to 
bind GlcNAc (Taylor et al., 1992; Taylor et al., 2005) but which is at the same time one of the 
most prominent aaMC markers (Franco and Fernández-Suárez, 2015), could be one of the 
microglial proteins which are affected by this microenvironment. As described above, other 
markers of aaMC such as Msa8a8, YM1 and Arginase1 were expressed more during the first 
disease exacerbation rather than during chronic disease. Although the regulation of CD206 
was not strong enough during the EAE course to be identified by RNA-Seq as one of the most 
highly regulated genes, the here presented data suggest that also CD206 is more highly 
expressed during the early disease, possibly even prior to the expression of Ms4a8a, YM1 
and Arginase1 at the exacerbation of the disease. Enhancement of aaMC responses could 
thus mediate beneficial properties not only by the secretion of anti-inflammatory cytokines, 
but also via a CD206-mediated upregulation of T cell engulfment. Exhaustion of lectin-
dependent T cell capture during the chronic state of the disease could be on the other hand 
mediated via the full establishment of inflammation. In this sense, it has been shown 
previously that expression of lectins such as CD206 is dependent on the inflammatory milieu 
and that IFN-γ is able to downregulate CD206 expression on microglia, which is followed by 
decreased pinocytotic capacities of microglia (Zimmer et al., 2003). 
4.6) Microglial T cell engulfment is distinct from cell-in-cell structures between other 
cell types 
While the engulfment and subsequent fate of living T cells in the CNS by microglia in vivo has 
not been reported so far, it has been previously shown that microglia can phagocytose other 
viable cell types such as neural precursor cells, neutrophils, neurons or synapses mainly in 
neurodevelopment (Brown and Neher, 2014; Neumann et al., 2008). In very few earlier 
neuropathological reports based on histological observations, cell-in-cell formation has been 
mentioned for lymphocytes in neurons (Hughes et al., 1968; Ng and Ling, 1999) and for 
oligodendrocytes in astrocytes (Shintaku and Yutani, 2004; Wu and Raine, 1992). However, 
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escape from microglial engulfment has not yet been described and therefore the here 
reported capability of T cells to break out from glial entrapment despite microglial attempts 
to engulf, highlights the great pathogenic potential of these T cells. According to in vitro 
observations, cell-in-cell structures have been reported previously also in other cell types, 
mostly for tumor cells (Yang and Li, 2012). The use of different vaguely defined terms, e.g., 
entosis, (suicide) emperipolesis, phagoptosis, cytophagocytosis or cannibalism indicate that 
both the physiological significance and underlying pathways of so-called cell-in-cell 
structures are still poorly understood (Brown and Neher, 2014; Overholtzer and Brugge, 
2008). As a comprehensive understanding and general consensus on the nomenclature in 
this field is still elusive, the general term “engulfment” was preferentially used in this thesis. 
Entosis was previously described as a form of cell cannibalism leading either to cell death or 
sometimes to escape (Krishna and Overholtzer, 2016), thus representing a dual fate of the 
engulfed cells comparable to the T cell fate described here. Different from activated Th17 
cells, however, entosis has so far mostly been assigned to homotypic cell-in-cell interactions 
(Krishna and Overholtzer, 2016). So far, a potential role of entosis in a non-cancerous 
context is not clear. Entosis-induced cell death has been shown to predominantly involve 
lysosomal degradation for the elimination of internalized cells whereas apoptosis of the 
target cell can compensate to execute cell death only after disruption of lysosomal function 
(Overholtzer et al., 2007). In the present work, Caspase-3/7 activity was identified in some 
internalized cells, not capable of escape, which is more in line with so-called suicide 
emperipolesis. This has been observed in autoimmune hepatitis, where autoreactive CD8+ T 
cells invade hepatocytes and die by apoptosis after internalization (Benseler et al., 2011). 
Thus, the here presented engulfment of viable T cells reflects a yet unknown process, clearly 
distinct from other cell-in-cell formation processes. In addition to the upregulation of typical 
aaMC responses, enhancement of T cell engulfment could thus serve as a new therapeutic 
target in MS. 
4.7) Targeting the activity of myeloid cells could serve as a new therapeutic strategy 
Both the upregulation of aaMC markers during the exacerbation of the disease as well as the 
engulfment of CNS-invading Th17 cells reflect myeloid cell-mediated mechanisms to 
counteract neuroinflammation. Thus, promotion of either aaMC functions or the engulfment 
of Th17 cells could serve as new therapeutic strategies for EAE and MS. A general induction 
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of the switch from caMC to aaMC would be highly desirable to counteract the disease. 
However, both IL-4 and glucocorticoids, which are able to mediate aaMC polarization, may 
partly result in side effects (Jiang et al., 2014; Tischner and Reichardt, 2007; Whitehead et 
al., 2002) and a more targeted pathway to promote aaMC effector functions may be more 
effective. Since Ms4a8a, YM1 and Arginase1 are highly regulated during the disease course 
and are thought to cause cardinal aaMC functions (4.2), a targeting of these proteins would 
be desirable to support beneficial properties of myeloid cells in the CNS. To translate the 
reported results from the mouse model to humans, it would be necessary to find human 
homologs of those genes. Regretfully, Arginase1 and YM1 were only reported to be markers 
for murine myeloid aaMC, but not for human aaMC (Raes et al., 2005). Similarly, Ms4a8a has 
not been described in human. Even though Ms4a8b was discussed as a potential functional 
human homolog of Ms4a8a in differentiated intestinal epithelium (Michel et al., 2013), the 
expression of Ms4a8b on human aaMC was not described and in vitro generation of human 
M2 macrophages from peripheral blood mononuclear cells did not result in Ms4a8b gene 
expression as analyzed by qRT-PCR (data not shown). Therefore, the question arises, which 
human proteins could fulfill the role of Arginase1, YM1 and Ms4a8a in humans to identify 
new therapeutic target molecules. Many human structural homologs of the Ms4a family are 
known, which could fulfill the function of the murine Ms4a8a in human. One human 
member of the Ms4a family which has been described to be expressed by human aaMC is 
Ms4a4a (Czimmerer et al., 2012; Ishibashi et al., 2001). Ms4a4a was already discussed as a 
therapeutic target for the treatment of multiple myelomas and could possibly serve also a 
specific target in MS, as its transcription seems so be limited to hematopoietic cells, mainly 
macrophages and plasma cells, thus revealing low potential of unfavorable side effects 
(Sanyal et al., 2017). Future in vitro and in vivo studies are needed to determine the 
molecular effector mechanisms of Ms4a8a, YM1 and Arginase1 proteins, and to identify 
which human genes could be responsible for similar effector mechanisms possibly serving as 
new therapeutic targets for the treatment of MS. Those studies could use genetic ablation or 
overexpression to gain new insight into disease mechanisms. Besides targeting the human 
functional homologues of Ms4a8a, YM1 and Arginase1, the directed manipulation of the 
beneficial capacities of myeloid cells in the CNS could ameliorate disease outcome. In this 
sense, it appears likely that the engulfment of living pathogenic T cells in order to protect the 
CNS tissue would be beneficial not only in mice but also in human, as T cells were also 
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described in human to invade the CNS during MS (Dendrou et al., 2015). The unique ability 
of T cells to migrate through microglia without subsequent cell death and to instead escape 
from those engulfments, which may explain the low overall engulfment rate, reveals a newly 
discovered mechanism strengthening their pathological potency in CNS inflammation. Thus, 
inhibiting the escape from microglial engulfment could serve as an additional target during 
MS. Of note, the lectin CD206, which was identified here to be associated with elevated 
engulfment capacities of microglia and which is able to bind GlcNAc on activated T cells, is 
not only expressed on murine but also on human myeloid cells (Franco and Fernández-
Suárez, 2015). Pharmacological enhancement of lectin expression on myeloid cells might 
thus promote T cell clearance during EAE and MS. Comparably to other aaMC markers, 
CD206 expression is driven by the transcription factor STAT6 and JAK-STAT signaling via 
binding of IL-4 or IL-13 to their receptor promotes CD206 expression (Lawrence and Natoli, 
2011). Furthermore, glucocorticoids also induce CD206 expression (Franco and Fernández-
Suárez, 2015). However, it would be of interest whether other pathways impact CD206 with 
higher specificities compared to IL-4/IL-13- or glucocorticoid-treatment. An increased 
expression of CD206 could not only increase the engulfment of viable T cells but also the 
phagocytosis of apoptotic cells via GlcNAc recognition on apoptotic cells (Duvall et al., 1985). 
As the phagocytosis of apoptotic cells has been shown to promote tissue repair during MS 
(Neumann et al., 2009), enhancement of CD206 expression on myeloid cells would hence 
promote two synergic beneficial properties of myeloid cells. CD206 is further involved in the 
recognition of various pathogenic microorganisms, including bacteria, fungi, virus, and 
parasites (Azad et al., 2014). Increased CD206 could thus even support immune defense 
mechanisms. 
4.8) Conclusion and Outlook 
This work demonstrates the ability of myeloid cells in the CNS of EAE-diseased animals to 
adapt their phenotype to different disease states and furthermore, to actively react to T cell 
infiltration during the disease by engulfing the infiltrating cells. Supporting the beneficial 
properties of myeloid cells in the CNS could thus serve as a new therapeutic target in the 
treatment of MS. Although available MS therapeutics partially effect myeloid cells already, 
they are often accompanied by side effects and higher specificities of therapeutics would be 
desirable. As described here, myeloid cells in the CNS are not only able to engulf invading T 
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cells, but also to switch to an anti-inflammatory phenotype by adapting their gene 
expression patterns. In order to investigate whether T cell engulfment is coupled to other 
beneficial effects of myeloid cells, additional experiments are needed to analyze how 
beneficial aaMC react to T cell infiltration in comparison to detrimental caMC. Therefore, 
tissue-resident GFP-labeled microglia in organotypic hippocampal slices could be polarized 
into alternatively activated microglia by treating the slices with a mixture of 
IL-4/Dexamethasone and LPS, as it was performed similarly with BMDM in this thesis. 
Engulfment of fluorescently labeled viable T cells could then be visualized via two-photon 
imaging and compared to the engulfment capacity of un-polarized or classically activated 
microglia. In another approach, IL-4/Dexamethasone treatment and subsequent 
visualization of engulfment processes could be performed in vivo in EAE-diseased mice. In 
addition, the treatment of EAE-diseased animals with MS therapeutics and subsequent 
analysis of the effect on the engulfment capacities would allow further conclusions 
concerning the relevance of engulfment processes in MS patients. Since glatiramer acetate 
and fumarates have been reported previously to affect myeloid cell polarization, these 
approved MS-therapeutics would be possibly also able to enhance T cell capture. Thus, 
especially the effect of glatiramer acetate and fumarates on engulfment processes would be 
worthwhile to analyze in detail. In order to understand the beneficial effects of the 
engulfment of living cells more precisely in humans, it would be also necessary to investigate 
engulfment processes in human tissues. Although the visualization of kinetic processes such 
as microglial T cell engulfment is not feasible in humans, immunohistochemical analysis of 
human post mortem material from MS patients could be used to visualize the full 
engulfment of T cells by microglia in human tissue via confocal imaging. Similar to the 
caspase stainings which were performed here in organotypic hippocampal slices, caspase 
and other markers for apoptotic cells or dead cells could be used to minimize the 
consideration of the engulfment of non-viable cells in human post mortem material. To this 
end, a brief post mortem interval (less than 12 h) would be required to decrease the 
probability of nonapoptotic DNA strand breaks (Anderson et al., 1996; Tatton, 2000). In 
order to investigate their relevance for the engulfment process in human, engulfment 
mediators such as the lectin CD206 could be co-stained in these immunohistochemical 
stainings as well. Similar immunohistochemical experiments could be also performed ex vivo 
in the CNS tissue of EAE-diseased mice. Since not only the lectin CD206 but also other lectins 
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could mediate the recognition of GlcNAc-expressing activated T cells, immunohistochemistry 
could help to screen for other candidates to affect engulfment processes. In order to proof a 
beneficial capacity of T cell engulfment, antibody-mediated lectin neutralization could be 
performed in vivo in EAE-induced mice prior to the onset of the disease and during the 
disease course. In case of a beneficial effect of the engulfment processes, inhibition of these 
processes should result in exacerbated disease courses. However, as lectins such as CD206 
are not only expressed by microglia, but also by peripheral myeloid cells (Franco and 
Fernández-Suárez, 2015), it has to be taken into account that CD206 blockade could also 
impact peripheral phagocytosis. 
To understand the full extent of the impact of engulfment processes during the disease, it is 
of further interest, whether myeloid cells in the CNS are able to engulf other pathogenic 
autoimmune cells such as CD8+ T cells or B cells during the disease. In order to answer this 
question, organotypic hippocampal slices could be co-cultured with various immune cells. In 
vivo two-photon imaging of myeloid cells and T cells in peripheral organs such as the spleen 
could serve as a control of data obtained in the CNS and could thus provide deeper insight 
into the relevance of this process in the CNS as the target organ of the disease. These 
experiments would also determine, whether peripheral myeloid cells are able to contribute 
to microglial T cell capture. Of note, some T cells were able to escape microglial engulfment 
and high percentages of T cells were not engulfed in the CNS despite the high expression of 
GlcNAc in the CNS. In order to determine how T cell capture is circumvented by pathogenic T 
cells, laser capture microdissection could be used followed by RNA-Seq to compare the gene 
expression profile of engulfed and freely migrating T cell in the CNS. Differences in the gene 
expression profile could reveal additional pathways which mediate T cell engulfment or 
escape, which could in turn reveal more therapeutic targets. 
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Appendix 
Abbreviations 
Abbreviation Meaning 
aaBMDM alternatively activated Bone Marrow-Derived 
Macrophages 
aaMC alternatively activated Myeloid Cell(s) 
APC Antigen Presenting Cell(s) 
ANOVA Analysis Of Variance 
BMDC Bone Marrow-derived Dendritic Cells 
BMDM Bone Marrow-Derived Macrophages 
BME Basal Medium Eagle  
BSA Bovine Serum Albumin 
caMC classically activated Myeloid Cell(s) 
cDNA Complementary Deoxyribonucleic Acid 
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